愛齊科技 (ALGN) 2019 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to the Align Technologies Fourth Quarter and Full Year 2019 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

    各位好,歡迎參加 Align Technologies 2019 年第四季暨全年財報電話會議。(接線員指示) 提醒各位,本次會議將被錄音。

  • It is now my pleasure to introduce your host, Shirley Stacy, Vice President, Corporate and Investor Communications. Thank you, Ms. Stacy. You may begin.

    現在很榮幸為各位介紹今天的主持人:企業與投資人溝通副總裁 Shirley Stacy。謝謝您,Stacy 女士。您可以開始了。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications, Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO.

    各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。

  • We issued fourth quarter and full year 2019 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available today by 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on February 12. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13697560 followed by pound. International callers should dial (201) 612-7415 with the same conference number.

    我們今天已透過 GlobeNewswire 發布 2019 年第四季暨全年財務結果,可於我們網站 investor.aligntech.com 查閱。今天的電話會議將以音訊網路直播,並會在我們網站上存檔約 1 個月。電話重播將於今天下午 5:30(美東時間)提供,至 2 月 12 日下午 5:30(美東時間)止。如需收聽電話重播,美國境內來電者請撥 (877) 660-6853,輸入會議編號 13697560 後按井字鍵。國際來電者請撥 (201) 612-7415,並使用相同的會議編號。

  • As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the first quarter and fiscal year outlook for 2020. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statement.

    提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及對 2020 年第一季預期財務結果與 2020 會計年度展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明,該等報告可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。

  • We've posted historical financial statements, including the corresponding reconciliation and our fourth quarter and full year 2019 conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.

    我們已在網站「季度業績」(Quarterly Results) 頁面上張貼歷史財務報表(包括相應的調節表),以及 2019 年第四季暨全年財報電話會議投影片。如需更詳細資訊,請參閱這些檔案。

  • With that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    接下來,我想把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Shirley. Good afternoon, and thanks for joining us.

    謝謝你,Shirley。各位下午好,感謝各位加入我們。

  • On our call today, I'll provide some highlights from the fourth quarter and full year then briefly discuss the performance of our 2 operating segments, clear aligners and intraoral scanners. John will provide more detail on our financial results, discuss our outlook for the first quarter and share our high-level thoughts about 2020. Following that, I'll come back and summarize a few key points and open up the call to questions.

    在今天的電話會議中,我將先提供第四季與全年的一些重點,接著簡要說明我們兩個營運部門——透明牙套與口內掃描器——的表現。John 將更詳細說明我們的財務結果、討論第一季展望,並分享我們對 2020 年的高層次看法。之後我會回來總結幾個關鍵重點,並開放提問。

  • Our fourth quarter was a strong finish to a great year with record revenues and volumes. Q4 Invisalign shipments increased 23.9% year-over-year and marked another major milestone with our 8 millionth Invisalign patient who started treatment in December. This rate of growth is really amazing to me given our 7 millionth Invisalign patient was just this past May, 7 months ago. For Q4, iTero scanner revenues increased 20.2% year-over-year with strong growth, especially from international doctors.

    我們第四季為精彩的一年畫下強勁句點,營收與出貨量皆創新高。第四季 Invisalign 出貨量年增 23.9%,並達成另一個重要里程碑:第 800 萬位 Invisalign 病患於 12 月開始治療。考量到第 700 萬位 Invisalign 病患是在去年 5 月、也就是僅 7 個月前才達成,這樣的成長速度令我非常驚訝。第四季 iTero 掃描器營收年增 20.2%,成長強勁,尤其來自國際醫師的成長表現突出。

  • On a sequential basis, Invisalign volumes were up 7.4%, driven by strong growth in North America, EMEA and Latin America, with all-time highs in those regions. We also saw strong growth from Invisalign Go systems across all regions, reflecting continued progress with GP dentists as well as a ramp-up from Invisalign Moderate, which launched at the beginning of Q4 in North America. For the quarter, we shipped Invisalign cases to approximately 67,000 doctors, of which 7,200 were first time customers. We also trained over 5,500 new doctors in Q4, including 3,400 international doctors.

    以季比來看,Invisalign 出貨量成長 7.4%,主要由北美、EMEA 與拉丁美洲的強勁成長所帶動,且這些地區皆創下歷史新高。我們也看到 Invisalign Go 系統在各地區均有強勁成長,反映我們在一般牙醫(GP)端的持續進展,以及 Invisalign Moderate 在第四季初於北美上市後的放量。本季我們向約 67,000 位醫師出貨 Invisalign 病例,其中 7,200 位為首次購買客戶。我們在第四季也訓練了超過 5,500 位新醫師,其中包括 3,400 位國際醫師。

  • For the full year, total revenues of $2.4 billion reflect record revenues, up 22.4% year-over-year, includes $2 billion in clear aligner revenues. In 2019, Invisalign volumes were up 24.2% year-over-year and iTero scanner revenues were up 38.5% year-over-year. During the year, over 1.5 million people started treatment with Invisalign clear aligners worldwide, including 447,000 teens and younger patients, which was up 34.1%.

    全年總營收 24 億美元反映營收創新高,年增 22.4%,其中包含 20 億美元的透明牙套營收。2019 年,Invisalign 出貨量年增 24.2%,iTero 掃描器營收年增 38.5%。全年全球有超過 150 萬人開始使用 Invisalign 透明牙套治療,其中包含 447,000 名青少年與更年輕的患者,年增 34.1%。

  • Now let's turn to the specifics around our fourth quarter results, starting with the Americas region. For the Americas region, Q4 Invisalign case volume was up 4.9% sequentially and up 19.3% year-over-year. On a sequential basis, Q4 results reflect strong growth from North American GP dentists as well as continued strength from Latin American doctors. Year-over-year growth for Q4 reflects continued adoption of Invisalign treatment from both orthodontists and GP dentist channels, which were up 20.5% and 17.3%, respectively. Latin America volume was up 79% year-over-year, led by continued strong growth from Brazil. For the full year, Americas Invisalign volume was up 17.5%.

    接下來我們談第四季業績細節,先從美洲地區開始。美洲地區第四季 Invisalign 病例量季增 4.9%,年增 19.3%。以季比來看,第四季結果反映北美一般牙醫的強勁成長,以及拉丁美洲醫師的持續強勢表現。以年比來看,第四季成長反映 Invisalign 治療在矯正專科醫師與一般牙醫通路的持續採用,兩者分別年增 20.5% 與 17.3%。拉丁美洲病例量年增 79%,主要由巴西的持續強勁成長帶動。全年美洲 Invisalign 病例量年增 17.5%。

  • For our international business, Q4 was a great quarter with Invisalign case volume up 10.5% sequentially, driven by strong growth in the EMEA region, rebounding from Q3 '19 summer holidays and offset somewhat by slower growth in APAC, specifically China. On a year-over-year basis, strong Invisalign volume of 30.1% reflects increased utilization and continued expansion of our customer base in both EMEA and Asia Pacific region. In Q4, we trained over 3,400 new Invisalign doctors internationally and roughly 55% in EMEA and 45% in APAC.

    在國際業務方面,第四季表現非常出色,Invisalign 病例量季增 10.5%,主要由 EMEA 地區強勁成長帶動,從 2019 年第三季暑期假期後回升;但部分被 APAC(特別是中國)較慢的成長所抵銷。以年比來看,Invisalign 病例量強勁成長 30.1%,反映在 EMEA 與亞太地區客戶使用率提升,以及客戶基礎持續擴張。第四季我們在國際市場訓練了超過 3,400 位新的 Invisalign 醫師,其中約 55% 在 EMEA、45% 在 APAC。

  • For the year, international volume was up 34% year-on-year.

    全年國際病例量年增 34%。

  • In EMEA, Q4 was a strong quarter. Volumes were up 37.3% sequentially, driven by growth in all core markets, primarily from Spain and Italy, as well as from the teen segment which was up 50.6% from Q3 '19. On a year-over-year basis, Invisalign volume was up 31.5%, driven by growth in all core country markets, including the teen segment, which was up 38.7% from the prior year.

    在 EMEA,第四季表現強勁。病例量季增 37.3%,由所有核心市場的成長所帶動,主要來自西班牙與義大利;同時青少年族群較 2019 年第三季成長 50.6%。以年比來看,Invisalign 病例量年增 31.5%,由所有核心國家市場的成長所帶動;其中青少年族群較去年同期成長 38.7%。

  • For the full year, EMEA volume was up 34.2%, led by Spain, Italy and France, as well as our key expansion markets led by Turkey, the Middle East and Africa region and Russia.

    全年 EMEA 病例量年增 34.2%,由西班牙、義大利與法國領先帶動;同時我們的關鍵擴張市場亦有成長,主要由土耳其、中東與非洲地區以及俄羅斯帶動。

  • For APAC, Q4 was down sequentially, as expected, following a very strong Q3 '19 teen season in China as well as less-than-expected volume from adults, partially offset by strong volume growth from Japan. We believe the ongoing U.S.-China trade war and economic uncertainty remained a headwind for our consumer demand, especially for consumption of luxury goods and considered purchases.

    在 APAC,第四季如預期呈現季減,主要因中國在 2019 年第三季青少年旺季表現非常強勁,以及成人病例量低於預期;但部分被日本的強勁病例量成長所抵銷。我們認為持續的美中貿易戰與經濟不確定性仍是消費需求的逆風,尤其影響奢侈品與審慎型消費的支出。

  • On a year-over-year basis, APAC volume was up 28%, driven by growth across the region, led by Japan, Australia, New Zealand, Southeast Asia. For the year, APAC volume was up 33.7%.

    以年對年基準計算,亞太地區(APAC)出貨量成長28%,主要受惠於區域內全面成長,其中以日本、澳洲、紐西蘭與東南亞領先。全年而言,亞太地區出貨量成長33.7%。

  • Overall for the teen market, in Q4, approximately 116,000 teenagers started treatment with Invisalign clear aligners, an increase of 33.1% year-over-year, driven by continued strong adoption across all major regions.

    整體就青少年市場而言,第四季約有116,000名青少年開始使用Invisalign隱形矯正器進行治療,年對年成長33.1%,主要由各主要區域持續強勁的採用所帶動。

  • For the full year, total teen cases worldwide grew 34.1% to approximately 447,000 teenagers or 29.3% of our total volume. I'm pleased with our progress treating teenagers and younger kids and the continued strong adoption of Invisalign clear aligners globally.

    全年而言,全球青少年病例總數成長34.1%,至約447,000名青少年,占我們總出貨量的29.3%。我對我們在治療青少年與更年幼孩童方面的進展,以及Invisalign隱形矯正器在全球持續強勁的採用感到欣慰。

  • For 2019, Invisalign treatment with mandibular advancement was up 85% year-over-year and Invisalign First was up 455% year-over-year for a cumulative total of 41,500 cases and 32,400 cases to date, respectively.

    2019年,具下顎前移功能(mandibular advancement)的Invisalign治療年對年成長85%,而Invisalign First年對年成長455%;截至目前累計總病例數分別為41,500例與32,400例。

  • Product technology and innovation continues to be a key growth driver across our regions. Over the past year, we launched several new Invisalign offerings for both comprehensive and noncomprehensive treatment, giving doctors more tools and choices to treat a greater range of cases from adults to teenagers, and now kids as young as 7 years old as well as new treatment options and technology designed to appeal to consumers who are considering or starting Invisalign treatment.

    產品技術與創新持續是我們各區域的關鍵成長動能。過去一年,我們推出多項新的Invisalign產品,涵蓋完整與非完整療程,讓醫師擁有更多工具與選擇,可治療從成人到青少年、以及現在最小7歲孩童的更廣泛病例,同時也推出新的治療選項與技術,旨在吸引正在考慮或開始Invisalign治療的消費者。

  • In Q4, we introduced the Invisalign Moderate Package, a 20-stage treatment option designed for consumers whose treatment goals fall between the existing Invisalign Lite and Invisalign Comprehensive packages and can be completed in the range of 5 to 12 months.

    第四季,我們推出Invisalign Moderate Package,這是一項20階段的治療選項,針對治療目標介於既有Invisalign Lite與Invisalign Comprehensive方案之間的消費者設計,療程可在約5至12個月內完成。

  • We launched SmileView, an online tool designed to help prospective Invisalign patients visualize a new, straighter smile before they opt for Invisalign treatment. Align's new SmileView visualization tool is designed to drive awareness and demand for teeth straitening using Invisalign treatment by engaging consumers and allowing them to see a simulation of what their smile could look like.

    我們推出SmileView,這是一項線上工具,旨在協助潛在的Invisalign患者在選擇Invisalign治療前,先行視覺化呈現更整齊的新笑容。Align全新的SmileView視覺化工具,透過與消費者互動並讓其看到笑容可能呈現的模擬效果,旨在提升對使用Invisalign治療進行牙齒矯正的認知與需求。

  • We also upgraded My Invisalign mobile app, which previously focused on patients already in treatment, but now includes several new features to help potential patients who are seeking information about teeth straightening treatment, including an in-app version of SmileView. Consumers can use the app to take a selfie and instantly visualize how their smile can transform after Invisalign treatment.

    我們也升級了My Invisalign行動App;該App過去主要聚焦於已在治療中的患者,但現在新增多項功能,以協助正在尋找牙齒矯正治療資訊的潛在患者,其中包含App內建版本的SmileView。消費者可使用該App自拍,並即時視覺化呈現其在完成Invisalign治療後笑容如何轉變。

  • Our consumer marketing efforts are designed to build the category and drive demand for Invisalign treatment through a doctor's office. We invest over $100 million each year in consumer marketing programs, including TV, digital and social media, PR, event marketing as well as our Patient Concierge program. Our goals are to make the Invisalign brand a household name worldwide and to motivate consumers to seek Invisalign treatment through a doctor's office.

    我們的消費者行銷工作旨在擴大品類並透過醫師診所推動Invisalign治療需求。我們每年在消費者行銷計畫上的投資超過1億美元,涵蓋電視、數位與社群媒體、公關、活動行銷,以及我們的Patient Concierge計畫。我們的目標是讓Invisalign品牌在全球成為家喻戶曉的名稱,並促使消費者透過醫師診所尋求Invisalign治療。

  • In Q4, we continue to see strong engagement with consumers and had over 5.3 million unique visitors on invisalign.com sites for a total of 18 million year-over-year. Other key metrics showed increased activity and engagement with the Invisalign brand and are included in our Q4 quarterly slides.

    第四季,我們持續看到消費者高度參與,invisalign.com各站點的單季不重複訪客超過530萬人,年對年累計達1,800萬人次。其他關鍵指標亦顯示Invisalign品牌活動度與互動度提升,相關內容已納入我們第四季季度簡報投影片。

  • For our iTero scanner and services business, Q4 was a very strong quarter with better-than-expected revenues, up 6.6% sequentially and 20.2% year-over-year, driven by strength from all regions. Q4 volumes reflect continued commercialization of the iTero Element 2 and Element Flex scanners, especially for orthodontists in North America, the continued rollout with our major DSO partners and increased sales internationally, especially in Japan.

    就我們的iTero掃描儀與服務業務而言,第四季表現非常強勁,營收優於預期,季對季成長6.6%、年對年成長20.2%,主要由各區域的強勁表現所帶動。第四季出貨量反映iTero Element 2與Element Flex掃描儀持續商業化推廣,尤其是在北美的矯正醫師族群;同時也反映我們與主要DSO合作夥伴的持續導入,以及國際銷售增加,特別是在日本。

  • 2019 was a great year for our iTero business with total revenues up 38.5% year-over-year. Cumulatively, over 20.5 million orthodontic scans and 4.7 million restorative scans have been performed with iTero scanners.

    2019年對我們的iTero業務而言是非常出色的一年,總營收年對年成長38.5%。累計而言,已使用iTero掃描儀完成超過2,050萬次矯正掃描與470萬次修復掃描。

  • Use of the iTero scanners for Invisalign case submission continues to grow and remains a positive catalyst for Invisalign utilization. For Q4, total Invisalign cases submitted with a digital scanner in the Americas increased to 79.5% from 73.5% in Q4 of last year. International scans increased to 64.7%, up from 57.5% in the same quarter last year. What's really exciting is to see that within the Americas, 93.3% of cases submitted by North American orthodontists are submitted digitally now.

    使用iTero掃描儀提交Invisalign病例的比例持續成長,並仍是推動Invisalign使用量的正向催化因素。第四季,美洲地區以數位掃描儀提交的Invisalign病例占比提升至79.5%,高於去年第四季的73.5%。國際市場的數位掃描占比提升至64.7%,高於去年同季的57.5%。更令人振奮的是,在美洲地區,北美矯正醫師提交的病例中,目前已有93.3%是以數位方式提交。

  • We are pleased with the continued progress of our iTero business and remain confident that it will continue to help drive our overall growth and help increase the adoption of our digital platform with Invisalign treatment.

    我們對iTero業務的持續進展感到滿意,並仍有信心其將持續協助推動我們的整體成長,並提升以Invisalign治療為核心的數位平台採用。

  • With that, I'll turn the call over to John.

    接下來,我把電話會議交給John。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Thanks, Joe.

    謝謝你,Joe。

  • Now for our Q4 financial results. Total revenue for the fourth quarter was $649.8 million, up 7% from the prior quarter and up 21.7% from the corresponding quarter a year ago.

    接著說明我們第四季的財務結果。第四季總營收為6.498億美元,較前一季成長7%,較去年同期成長21.7%。

  • For clear aligners, Q4 revenues of $543.6 million was up 5.3% sequentially, with strong Invisalign volume from EMEA and North America. Year-over-year, clear aligner revenues growth of 22% reflects strong Invisalign growth volume across all regions. Clear aligner revenue growth was unfavorably impacted by approximately 1.3 points year-over-year from foreign exchange.

    就隱形矯正器而言,第四季營收為5.436億美元,季對季成長5.3%,主要受惠於EMEA與北美Invisalign出貨量強勁。年對年而言,隱形矯正器營收成長22%,反映各區域Invisalign出貨量皆強勁成長。隱形矯正器營收成長年對年受到外匯不利影響約1.3個百分點。

  • Q4 Invisalign ASPs were down sequentially by approximately $20 to $1,240, primarily due to discounts, mix and unfavorable foreign exchange. On a year-over-year basis, Q4 Invisalign ASPs increased approximately $5, primarily reflecting price increases in all regions and increased additional aligner revenues, partially offset by promotional discounts and unfavorable foreign exchange and product mix shift.

    第四季Invisalign平均銷售單價(ASP)季對季下降約20美元至1,240美元,主要由折扣、產品組合與不利外匯所致。年對年而言,第四季Invisalign ASP增加約5美元,主要反映各區域價格上調及額外矯正器營收增加,但部分被促銷折扣、不利外匯與產品組合轉移所抵銷。

  • Total Q4 Invisalign shipments of 413,700 cases were up 7.4% sequentially and up 23.9% year-over-year.

    第四季Invisalign總出貨量為413,700例,季對季成長7.4%,年對年成長23.9%。

  • Our scanner and services revenue for the fourth quarter was $106.2 million, up 16.6% sequentially due to volume increases in EMEA and Americas. Year-over-year revenues were up 20.2%, primarily due to volume increases in EMEA, APAC and the Americas as well as higher services revenues from our increased installed base.

    第四季掃描儀與服務營收為1.062億美元,季對季成長16.6%,主要因EMEA與美洲地區出貨量增加。年對年營收成長20.2%,主要由EMEA、亞太與美洲地區出貨量增加所帶動,並受惠於裝機基數擴大帶來較高的服務營收。

  • Moving on to gross margin. Fourth quarter overall gross margin was 72.6%, up 0.6 points sequentially and up 0.9 points year-over-year.

    接著談毛利率。第四季整體毛利率為72.6%,季對季上升0.6個百分點,年對年上升0.9個百分點。

  • Clear aligner gross margin for the fourth quarter was 74.1%, up 0.6 points sequentially, primarily due to lower freight and training costs and lower number of aligners per case, partially offset by lower Invisalign ASPs. Clear aligner gross margin was flat year-over-year, primarily due to lower training costs and a slight increase in Invisalign ASPs, offset by an increase in aligners per case.

    第四季隱形矯正器毛利率為74.1%,季對季上升0.6個百分點,主要因運費與培訓成本降低,以及每例所需矯正器數量減少;但部分被較低的Invisalign ASP所抵銷。隱形矯正器毛利率年對年持平,主要因培訓成本降低與Invisalign ASP小幅上升,但被每例矯正器數量增加所抵銷。

  • Scanner gross margin for the fourth quarter was 64.9%, up 0.8 points sequentially, primarily due to manufacturing efficiencies, partially offset by lower ASPs, and up 5 points year-over-year primarily due to manufacturing efficiencies and higher service revenue and scanner ASPs.

    第四季掃描器毛利率為64.9%,較前一季上升0.8個百分點,主要由於製造效率提升,部分被較低的平均銷售價格(ASP)所抵銷;較去年同期上升5個百分點,主要同樣受惠於製造效率提升,以及較高的服務營收與掃描器ASP。

  • Q4 operating expenses were $320.8 million, up sequentially 3.4% and up 22.2% year-over-year. The sequential increase in operating expenses primarily reflects our continued investment in sales and marketing and R&D activities, partially offset by lower litigation expenses. Additionally, the third quarter included a $6.8 million benefit from the settlement of our Invisalign store leases.

    第四季營業費用為3.208億美元,較前一季增加3.4%,較去年同期增加22.2%。營業費用的季增主要反映我們持續投資於銷售與行銷以及研發(R&D)活動,部分被較低的訴訟費用所抵銷。此外,第三季包含因和解我們Invisalign門市租約而帶來的680萬美元利益。

  • Year-over-year, the increase in operating expenses reflects higher spending commensurate with go-to-market activities, offset by lower legal expenses.

    與去年同期相比,營業費用增加反映與市場推廣(go-to-market)活動相稱的較高支出,並被較低的法律費用所抵銷。

  • Our fourth quarter operating income was $151.2 million, up 18.9% sequentially and up 25.5% year-over-year. Our fourth quarter operating margin was 23.3%, up 2.4 points sequentially and up 0.7 points year-over-year. The sequential increases in operating income and operating margin are primarily attributed to improved gross profit and reduction in litigation expenses.

    第四季營業利益為1.512億美元,較前一季增加18.9%,較去年同期增加25.5%。第四季營業利益率為23.3%,較前一季上升2.4個百分點,較去年同期上升0.7個百分點。營業利益與營業利益率的季增主要歸因於毛利改善以及訴訟費用下降。

  • Operating margin was impacted by approximately 0.6 points year-over-year from foreign exchange. The third quarter operating income included a $6.8 million benefit from the settlement of our Invisalign store leases, which increased Q3 operating margin by 1.1%. On a year-over-year basis, the increase in operating income and operating margin primarily reflects higher gross profit and operating leverage, partially offset by continued investment in R&D, geographic expansion and go-to-market activities.

    營業利益率較去年同期約受外匯影響0.6個百分點。第三季營業利益包含因和解我們Invisalign門市租約而帶來的680萬美元利益,使第三季營業利益率提高1.1%。以年增角度來看,營業利益與營業利益率的提升主要反映較高的毛利與營運槓桿,部分被持續投資於研發、地理擴張及市場推廣(go-to-market)活動所抵銷。

  • With regards to fourth quarter tax provision, our tax rate was 22.2%, which includes approximately $5.8 million of tax benefit related to a tax audit settlement.

    關於第四季所得稅費用,我們的稅率為22.2%,其中包含約580萬美元、與稅務稽核和解相關的稅務利益。

  • Fourth quarter diluted earnings per share was $1.53, up $0.25 sequentially and up $0.33 compared to the prior year.

    第四季稀釋每股盈餘為1.53美元,較前一季增加0.25美元,較去年同期增加0.33美元。

  • Moving on to the balance sheet. As of December 31, 2019, cash, cash equivalents and marketable securities, including both short and long-term investments, were $868.6 million, an increase of approximately $86.7 million from the prior quarter, which is primarily due to higher cash flow from operations. Of our $868.6 million of cash, cash equivalents and marketable securities, $590.1 million was held in the U.S. and $278.5 million was held by our international entities.

    接著看資產負債表。截至2019年12月31日,現金、約當現金及有價證券(包含短期與長期投資)為8.686億美元,較前一季增加約8,670萬美元,主要由於營運活動帶來較高的現金流。在8.686億美元的現金、約當現金及有價證券中,5.901億美元持有於美國,2.785億美元由我們的海外實體持有。

  • Q4 accounts receivable balance was $550.3 million, up approximately 3.5% sequentially. Our overall days sales outstanding was 76 days, down 3 days sequentially and up 2 days as compared to Q4 last year.

    第四季應收帳款餘額為5.503億美元,較前一季約增加3.5%。整體應收帳款週轉天數(DSO)為76天,較前一季減少3天,較去年第四季增加2天。

  • Cash flow from operations for the fourth quarter was $218.2 million. And free cash flow, defined as cash flow from operations less capital expenditures, amounted to $175.6 million. Our business continues to have a very strong cash generation.

    第四季營運活動現金流為2.182億美元。自由現金流(定義為營運活動現金流扣除資本支出)為1.756億美元。我們的業務持續具備非常強勁的現金創造能力。

  • Capital expenditures for the fourth quarter were $42.5 million, primarily related to our continued investment in increasing aligner capacity and facilities.

    第四季資本支出為4,250萬美元,主要與我們持續投資以提升隱形矯正器產能及設施相關。

  • During Q4 2019, we repurchased $100.5 million of our stock against our stock buyback authorization and have $100 million still available for repurchase under the May 2018 Repurchase Program.

    在2019年第四季,我們依據股票回購授權回購了1.005億美元的公司股票;在2018年5月回購計畫下,仍有1億美元可供回購。

  • Before we move to the Q1 outlook, I would like to make a few comments on our full year 2019 results. In 2019, we shipped a record 1.5 million Invisalign cases, up 24.2%. This reflects 34% volume growth from our international doctors and 17.5% volume growth from our Americas doctors.

    在我們進入第一季展望之前,我想先對2019年全年業績做幾點說明。2019年,我們出貨創紀錄的150萬件Invisalign案例,成長24.2%。這反映我們國際醫師出貨量成長34%,以及美洲地區醫師出貨量成長17.5%。

  • Shipments of our iTero scanner were up 29.7% over 2018.

    我們的iTero掃描器出貨量較2018年成長29.7%。

  • Total revenue was a record $2.4 billion, up 22.4% year-over-year, with clear aligner revenues of $2 billion, up 19.8% year-over-year. Clear aligner revenue growth was impacted by approximately 2.6 points year-over-year from foreign exchange.

    總營收創紀錄達24億美元,較去年同期成長22.4%;其中透明矯正器營收為20億美元,較去年同期成長19.8%。透明矯正器營收成長較去年同期約受外匯影響2.6個百分點。

  • 2019 iTero scanner and services revenues were a record $38.1 million (sic) [$381.1 million], up 38.5%.

    2019年iTero掃描器與服務營收創紀錄為3,810萬美元(原文如此)[$3.811億美元],成長38.5%。

  • Full year operating income of $542.5 million, up 16.3% versus 2018 and operating margin at 22.5%. 2019 operating income also includes a litigation benefit of $51 million and Invisalign store closure costs of $23 million for a net positive impact on operating margin of approximately 1.2%. Operating margin was unfavorably impacted by approximately 1 point year-over-year from foreign exchange.

    全年營業利益為5.425億美元,較2018年成長16.3%,營業利益率為22.5%。2019年營業利益亦包含5,100萬美元的訴訟利益,以及2,300萬美元的Invisalign門市關閉成本,對營業利益率的淨正面影響約為1.2%。營業利益率較去年同期約受外匯不利影響1個百分點。

  • Free cash flow was $597.6 million, up $266.2 million versus 2018.

    自由現金流為5.976億美元,較2018年增加2.662億美元。

  • For the year, we repurchased over 1.8 million shares of ALGN stock for $400 million.

    全年我們以4億美元回購超過180萬股ALGN股票。

  • 2019 diluted earnings per share was $5.53.

    2019年稀釋每股盈餘為5.53美元。

  • Before I comment on the demand outlook, I wanted to take a minute to talk about the corporate structure reorganization to relocate our European headquarters from the Netherlands to Switzerland in Q1 and the implication to our GAAP financials.

    在我評論需求展望之前,我想花一點時間談談公司架構重組:我們將於第一季把歐洲總部自荷蘭遷至瑞士,以及其對我們GAAP財務報表的影響。

  • As a result of the corporate structure reorganization to relocate our European headquarters from the Netherlands to Switzerland in Q1, our Q1 2020 GAAP tax rate will reflect a significant onetime tax benefit associated with the recognition of a deferred tax asset related to the intra-entity sale of certain intellectual property rights. This deferred tax benefit will be amortized starting in 2020 and will continue into subsequent quarters and years. The period over which this tax benefit will be recognized depends on the profitability of our Swiss headquarters and therefore is uncertain at this time. Management ordinarily assesses the health of our business with regard to these types of onetime events and believes this reorganization will make it difficult for investors to assess our core underlying financial performance were we to report solely based on GAAP. Therefore, we will supplement our GAAP information with non-GAAP measures going forward. Beginning in Q1 2020, in addition to our GAAP results, we will present non-GAAP measures that exclude the aforementioned tax impact, along with certain other items that may not be indicative of our fundamental operating performance, including discrete cash and noncash charges, in order to present investors with greater transparency into our core business operations.

    由於公司架構重組、於第一季將歐洲總部自荷蘭遷至瑞士,我們2020年第一季GAAP稅率將反映一項重大的一次性稅務利益,該利益與確認一項遞延所得稅資產有關,而該遞延所得稅資產源自於集團內部出售某些智慧財產權。此遞延稅務利益將自2020年起攤銷,並延續至後續季度與年度。此稅務利益可被認列的期間取決於我們瑞士總部的獲利能力,因此目前仍不確定。管理層通常會在評估此類一次性事件時衡量我們業務的健康狀況,並認為若僅依GAAP報導,該重組將使投資人難以評估我們核心的基礎財務表現。因此,未來我們將以非GAAP衡量指標補充GAAP資訊。自2020年第一季起,除GAAP結果外,我們也將提供非GAAP指標,排除前述稅務影響,以及其他可能無法反映我們基本營運表現的項目(包括一次性的現金與非現金費用),以便讓投資人更透明地了解我們核心業務營運。

  • We will present GAAP, non-GAAP and a reconciliation in our earnings release and conference call materials.

    我們將在財報新聞稿與電話會議資料中提供GAAP、非GAAP以及調節表。

  • With that, let's turn to our Q1 outlook and the factors that inform our view. Q4 was a strong quarter with record volumes, and we expect to enter Q1 with this momentum from both the Americas and the EMEA regions.

    接下來我們來看第一季展望,以及支撐我們觀點的因素。第四季表現強勁、出貨量創新高,我們預期在美洲與EMEA地區的動能帶動下進入第一季。

  • For the Americas region, we expect Q1 to increase sequentially with growth from North America orthodontists and GP dentists.

    就美洲地區而言,我們預期第一季將較前一季成長,成長動能來自北美的矯正專科醫師與一般牙醫(GP)。

  • For international, we expect Q1 volumes to be down sequentially. We expect demand to be up sequentially as momentum continues from Q4. However, we expect the growth to be offset by a sequential decrease in APAC, primarily due to the expected impact from the novel coronavirus in China.

    就國際市場而言,我們預期第一季出貨量將較前一季下滑。隨著第四季延續的動能,我們預期需求將較前一季上升。然而,我們預期成長將被亞太地區(APAC)較前一季的下滑所抵銷,主要原因是預期中國新型冠狀病毒的影響。

  • We expect our iTero business to be down sequentially, following a seasonally strong Q4 and consistent with seasonal trends in capital equipment market and fewer sales in China.

    我們預期 iTero 業務將較前一季下滑,原因是第四季季節性表現強勁,且符合資本設備市場的季節性趨勢,以及中國銷售量較少。

  • Many of you have been following the news regarding the recent outbreak of the novel coronavirus in Wuhan, the capital of the Hubei province in China. China is one of our largest country markets and represents roughly 8% of our total revenues. It is home to hundreds of employees across China. Thankfully, we are not aware of any employee or family member who has contracted the novel coronavirus.

    你們許多人一直在關注有關中國湖北省省會武漢近期爆發新型冠狀病毒的新聞。中國是我們最大的單一國家市場之一,約占我們總營收的 8%。我們在中國各地有數百名員工。所幸的是,我們目前未得知有任何員工或其家屬感染新型冠狀病毒。

  • The situation in China is very fluid, and we are closely monitoring it. We are in contact with all relevant agencies globally. The Chinese government has implemented travel bans and has essentially shut down public transportation in Wuhan. It has also issued public warnings to avoid all nonessential medical and dental procedures for the time being. Some government-run hospitals and private clinics are following suit by instructing patients to stay home unless it's an emergency.

    中國的情勢變化非常快速,我們正密切監控。我們已與全球所有相關機構保持聯繫。中國政府已實施旅行禁令,並基本上關閉武漢的公共交通。同時也發布公告,提醒暫時避免所有非必要的醫療與牙科處置。部分公立醫院與私人診所也採取相同行動,指示病患除非緊急狀況,否則留在家中。

  • While we do not believe there is any impact to our product safety due to the stringent health and safety procedures ingrained in our manufacturing processes, we are taking additional precautions across China to minimize the risk of spreading illness to our internal teams, including additional protections and health screening procedures as well as travel restrictions. Given the increased uncertainty and disruption to our employees, doctors' practices, their patients and consumers, we believe it is prudent to reduce our outlook for Q1 to reflect the increased risk.

    雖然我們不認為由於製造流程中根深蒂固且嚴格的健康與安全程序,會對產品安全造成任何影響,但我們仍在中國各地採取額外預防措施,以降低疾病在內部團隊間傳播的風險,包括加強防護與健康篩檢程序,以及旅行限制。鑑於不確定性增加,以及對員工、醫師診所、其病患與消費者造成的干擾,我們認為審慎起見,應下調第一季展望以反映風險上升。

  • Therefore, for Q1, our outlook reflects approximately 20,000 to 25,000 less Invisalign cases and $30 million to $35 million less revenues for Invisalign and iTero products sold in China.

    因此,就第一季而言,我們的展望反映:Invisalign 病例數約減少 20,000 至 25,000 例,以及在中國銷售的 Invisalign 與 iTero 產品營收約減少 3,000 萬至 3,500 萬美元。

  • In addition, we are also absorbing $3 million to $4 million in idle China manufacturing plant and treatment planning capacity, which results in approximately 0.5% gross margin impact.

    此外,我們也將吸收中國製造工廠與治療規劃產能閒置所產生的 300 萬至 400 萬美元成本,約造成 0.5% 的毛利率影響。

  • With this as a backdrop, we expect the first quarter to shape up as follows: Invisalign case volume is expected to be in the range of 396,000 to 406,000 cases, up approximately 13% to 16% year-over-year.

    在此背景下,我們預期第一季表現如下:Invisalign 病例量預計介於 396,000 至 406,000 例,年增約 13% 至 16%。

  • We expect Q1 revenues to be in the range of $615 million to $630 million, up by approximately 12% to 15% year-over-year. Our supply agreement with SDC was terminated December 31, 2019 and hence our Q1 2020 revenue outlook does not reflect any SDC volume as compared to the same quarter a year ago when non-Invisalign aligners supplied to SDC contributed about $5.7 million to revenue.

    我們預期第一季營收介於 6.15 億至 6.30 億美元,年增約 12% 至 15%。我們與 SDC 的供應協議已於 2019 年 12 月 31 日終止,因此我們對 2020 年第一季的營收展望不包含任何 SDC 的出貨量;相較之下,一年前同季我們供應給 SDC 的非 Invisalign 隱形矯正器約貢獻 570 萬美元營收。

  • On a GAAP basis, we expect Q1 gross margin to be in the range of 71.5% to 72%. Q1 gross margin is expected to be down sequentially from slightly lower ASPs, driven by lower mix of China volume and idle China manufacturing and treatment planning capacity in our facility in Ziyang.

    以 GAAP 基礎計算,我們預期第一季毛利率介於 71.5% 至 72%。第一季毛利率預期將較前一季下滑,原因是平均售價(ASP)略降,主要受中國出貨量占比降低,以及我們資陽廠中國製造與治療規劃產能閒置所影響。

  • On a non-GAAP basis, we expect Q1 gross margin to be in the range of 71.7% to 72.2%, excluding stock-based compensation from gross profit. We expect Q1 GAAP operating expenses to be in the range of $345 million to $350 million, which reflects our continued investments in go-to-market activities along with our annual increase in employee compensation expenses.

    以非 GAAP 基礎計算,我們預期第一季毛利率介於 71.7% 至 72.2%,即自毛利中排除以股份為基礎的薪酬。我們預期第一季 GAAP 營業費用介於 3.45 億至 3.50 億美元,反映我們持續投入市場推廣(go-to-market)活動,以及員工薪酬費用的年度增加。

  • On a GAAP basis, Q1 operating margin is expected to be in the range of 15.4% to 16.5%. On a non-GAAP basis, we expect operating margin to be in the range of 19.5% to 20.5%, excluding stock-based compensation from operating income.

    以 GAAP 基礎計算,第一季營業利益率預期介於 15.4% 至 16.5%。以非 GAAP 基礎計算,我們預期營業利益率介於 19.5% 至 20.5%,即自營業利益中排除以股份為基礎的薪酬。

  • On a GAAP basis, our effective tax rate is expected to be approximately negative 1,400%, which includes approximately $1.4 billion of tax benefit associated with the recognition of a deferred tax asset related to the intra-entity sale of certain intellectual property rights resulting from our corporate structure reorganization. This deferred tax benefit will be amortized starting in 2020 and continue into subsequent quarters and years. The period over which the tax benefit will be recognized depends on the profitability of our Swiss headquarters and therefore is uncertain at this time. On a non-GAAP basis, excluding the onetime benefit from the intra-entity sale of certain IP rights, as mentioned above, and the tax benefits related to stock-based compensation, we expect our tax rate for Q1 2020 to range from approximately 22% to 23%.

    以 GAAP 基礎計算,我們的有效稅率預期約為負 1,400%,其中包含約 14 億美元的稅務利益,係與我們公司架構重組所導致之企業內部(intra-entity)出售特定智慧財產權相關的遞延所得稅資產認列。此遞延稅務利益將自 2020 年起攤銷,並延續至後續季度與年度。稅務利益可被認列的期間取決於我們瑞士總部的獲利能力,因此目前仍不確定。以非 GAAP 基礎計算,排除上述企業內部出售特定 IP 權利的一次性利益,以及與以股份為基礎的薪酬相關的稅務利益後,我們預期 2020 年第一季稅率約介於 22% 至 23%。

  • Diluted shares outstanding should be approximately 79.1 million, exclusive of any share repurchases.

    稀釋後流通在外股數應約為 7,910 萬股,不含任何庫藏股回購。

  • Taken together, we expect our Q1 2020 GAAP diluted earnings per share to be in the range of $18.65 to $18.74. Non-GAAP diluted earnings per share is expected to be in the range of $1.19 to $1.28 from excluding the onetime tax benefit from the intra-entity sale of IP rights, as mentioned above, and the stock-based compensation-related expenses.

    綜合以上,我們預期 2020 年第一季 GAAP 稀釋後每股盈餘介於 18.65 美元至 18.74 美元。非 GAAP 稀釋後每股盈餘預期介於 1.19 美元至 1.28 美元,係排除上述企業內部出售 IP 權利的一次性稅務利益,以及與以股份為基礎的薪酬相關的費用。

  • In addition, as we continue our operational expansion efforts, we expect capital expenditures for Q1 to be approximately $95 million to $100 million, and we expect depreciation and amortization to be $23 million to $25 million.

    此外,隨著我們持續推動營運擴張,我們預期第一季資本支出約為 9,500 萬至 1 億美元,折舊與攤銷預期為 2,300 萬至 2,500 萬美元。

  • Now let me turn to our view for the full year 2020. As I just described, the situation in China surrounding the novel coronavirus is very fluid. While our Q1 outlook includes our best view of how the coronavirus will impact our business in the first quarter, it is very difficult to predict and forecast the longer-term impact. Therefore, we are providing you with our best view of 2020 prior to the novel coronavirus outbreak so that you can use it as a baseline from which to build your models for the year. This means that you will need to make your own assumptions about how the coronavirus outbreak impacts our business over the remainder of 2020. Beyond the Q1 outlook and our commentary for 2020 below, we will not provide specific 2020 guidance at this time. We will continue to monitor the situation closely and update these comments when appropriate.

    接下來我談談我們對 2020 全年的看法。如我剛才所述,中國新型冠狀病毒相關情勢變化非常快速。雖然我們的第一季展望已納入我們對病毒在第一季對業務影響的最佳判斷,但要預測與推估較長期的影響非常困難。因此,我們將提供在新型冠狀病毒爆發前我們對 2020 年的最佳看法,讓你們可將其作為基準,用以建立今年的模型。這表示你們需要自行假設新型冠狀病毒疫情在 2020 年剩餘期間對我們業務的影響。除第一季展望以及下方我們對 2020 年的評論外,我們目前不會提供 2020 年的具體指引。我們將持續密切監控情勢,並在適當時更新上述評論。

  • With that, our outlook for 2020, notwithstanding the impact of foreign exchange rates and the novel coronavirus, is as follows: We anticipate total revenue growth for the company, Invisalign and iTero to be at the low end of our long-term operating model target of 20% to 30%.

    在此之下,我們對 2020 年的展望(不考慮匯率與新型冠狀病毒的影響)如下:我們預期公司整體、Invisalign 與 iTero 的總營收成長將落在我們長期營運模型目標 20% 至 30% 的低端。

  • We anticipate Invisalign volume to be at the low end of our long-term growth model target of 20% to 30%.

    我們預期 Invisalign 出貨量將落在我們長期成長模型目標 20% 至 30% 的低端。

  • On a GAAP basis, we anticipate 2020 operating margin to be slightly above our 2019 operating margin of 22.5%. We also expect our long-term operating margin range of 25% to 30% to remain unchanged. On a non-GAAP basis, we expect 2020 operating margin to be approximately 3.5% higher than our GAAP operating margin, excluding stock-based compensation from operating income.

    以 GAAP 基礎計算,我們預期 2020 年營業利益率將略高於 2019 年的 22.5%。我們也預期長期營業利益率區間 25% 至 30% 維持不變。以非 GAAP 基礎計算,排除以股份為基礎的薪酬對營業利益的影響後,我們預期 2020 年營業利益率將較 GAAP 營業利益率高約 3.5%。

  • On a GAAP basis, our 2020 tax provision will include approximately $1.4 billion of tax benefit in Q1 associated with the recognition of a deferred tax asset related to the intra-entity sale of certain intellectual property rights. This deferred tax benefit will be amortized starting in 2020 and continue into subsequent quarters and years. The period over which this tax benefit will be recognized depends on the profitability of our Swiss headquarters and therefore is uncertain at this time. On a non-GAAP basis, excluding the onetime tax benefit from the intra-entity sale of certain IP rights, as mentioned above, and the tax benefits related to stock-based compensation, we expect our tax rate for 2020 to range from approximately 22% to 23%.

    按照美國通用會計準則(GAAP)基礎,我們2020年的所得稅費用將在第一季包含約14億美元的稅務利益,與確認一項遞延所得稅資產有關,該資產源自於集團內部就若干智慧財產權進行的內部交易出售。此項遞延所得稅利益將自2020年起開始攤銷,並延續至後續季度及年度。此項稅務利益可被認列的期間取決於我們瑞士總部的獲利能力,因此目前仍不確定。按非GAAP基礎,排除上述因集團內部出售若干IP權利所產生的一次性稅務利益,以及與股票基礎薪酬相關的稅務利益後,我們預期2020年的稅率約介於22%至23%。

  • With that, I'll turn it back over to Joe for final comments. Joe?

    那麼,我把電話交回給Joe做最後的評論。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, John, and thanks to those of you joining our call today.

    謝謝你,John,也感謝各位今天加入我們的電話會議。

  • Overall, 2019 was a great year for Align, and I'm very pleased with the strong performance for both our Invisalign and iTero businesses. Not only did we celebrate our 22nd year in business, but we also achieved several major milestones, including our 8 millionth Invisalign patient, $2.4 billion in revenue for the first time.

    整體而言,2019年對Align來說是非常出色的一年,我對我們Invisalign與iTero兩項業務的強勁表現感到非常滿意。我們不僅慶祝成立第22年,也達成多項重要里程碑,包括迎來第800萬位Invisalign患者,以及營收首次達到24億美元。

  • As we kick off 2020, we're very concerned for the safety and health of our employees, customers, doctors and their patients in China. Their well-being is our top priority, and we are doing what we can to ensure that they are in good hands. We are working with our local teams to donate medical supplies and provide funding to help combat the outbreak.

    在我們啟動2020年之際,我們非常關切在中國的員工、客戶、醫師及其患者的安全與健康。他們的福祉是我們的首要優先事項,我們正盡力確保他們獲得妥善照顧。我們正與當地團隊合作捐贈醫療物資並提供資金,以協助對抗疫情爆發。

  • Like SARS in 2003, the coronavirus is already having a major impact on China and may expand to other countries around the world. I saw and experienced this impact as the CEO of GE Healthcare. We expect that like SARS and MERS before it, in time the virus will be addressed, the markets will assume an equilibrium and our business in China will continue to grow. The timing of this is uncertain, but the future growth opportunity for our business in China is certain.

    如同2003年的SARS,新型冠狀病毒已對中國造成重大影響,並可能擴散至全球其他國家。我在擔任GE Healthcare執行長時曾親眼看到並親身經歷這種影響。我們預期,如同先前的SARS與MERS,隨著時間推移,病毒將會受到控制,市場將回到均衡,而我們在中國的業務也將持續成長。其時間點仍不確定,但我們在中國業務的未來成長機會是確定的。

  • While we are mindful of the increased uncertainty in China and its impact on our Q1 outlook, it's important to take a step back and remember that our business is broad and deep. We have a strong growth in other regions and are seeing strong momentum in the Americas, across EMEA and in all other countries in APAC, especially Japan, Australia/New Zealand, Southeast Asia, Taiwan and Korea.

    儘管我們留意到中國不確定性上升及其對第一季展望的影響,但重要的是退一步記住,我們的業務版圖廣且根基深厚。我們在其他地區維持強勁成長,並在美洲、EMEA以及亞太區其他所有國家看到強勁動能,尤其是日本、澳洲/紐西蘭、東南亞、台灣與韓國。

  • In closing, I want to share with you a few thoughts with you regarding the future of our industry. Never before have I seen an amount of change in products, technology, distribution channels and business models. Align has always believed that the market opportunity for clear aligners is significantly larger than the underlying orthodontic case starts each year. We believe that over 300 million people want a better smile and the best way to access that potential patients is through doctors, using a digital approach with iTero scanners and the Invisalign system. Our partnership with doctors is a critical part of how we win with consumers, and we will continue to insist that patients visit a doctor in person for Invisalign treatment.

    最後,我想與各位分享幾點關於我們產業未來的看法。我從未見過產品、技術、通路與商業模式出現如此巨大的變化。Align一向相信,透明牙套的市場機會遠大於每年新增的正畸病例起始量。我們相信有超過3億人想要更美的笑容,而觸及這些潛在患者的最佳方式,是透過醫師,並以iTero掃描儀與Invisalign系統的數位化方式進行。我們與醫師的合作夥伴關係,是我們贏得消費者的關鍵之一;我們也將持續堅持,患者必須親自就診,由醫師進行Invisalign治療。

  • If I could leave you with one thing, it's that Align is not just a provider of the best clear aligner in the industry, and our clear aligner is not just a piece of plastic. Align is founded on digital -- IT, data, artificial intelligence, software, algorithms, digital scanning and 3D printing. We are the largest mass customized business the world has ever seen. Each Invisalign aligner is the output of millions of lines of code and thousands of digital actions that allow us to ship 0.5 million customized Class II medical devices a day.

    如果只能留給各位一個重點,那就是Align不僅是業界最佳透明牙套的供應商,我們的透明牙套也不只是塑膠片。Align建立在數位之上——IT、資料、人工智慧、軟體、演算法、數位掃描與3D列印。我們是世界上前所未見、規模最大的量產客製化企業。每一副Invisalign牙套,都是數百萬行程式碼與數千個數位動作的產出,使我們每天能出貨50萬件客製化的第二類醫療器材。

  • As a digital leader, we must continue to provide doctors with the best technology and tools to help them treat any patient. In 2020, we expect to bring several new products and systems and services to market, but we must provide more than just individual products. In digital, you pick a platform, not a product. You pick a company you believe in for the long term. Digital dentistry is being driven by products like iTero scanners and Invisalign clear aligners, and we believe our digital platform is setting the foundation for the future of dentistry. Align and our doctor partners are sitting on the edge of one of the biggest areas of growth that dentistry has ever seen. I'm very excited about what this means for our business and continued growth prospects in 2020 and beyond as we continue to transform smiles and change lives.

    作為數位領導者,我們必須持續為醫師提供最佳技術與工具,協助他們治療任何患者。在2020年,我們預期將推出多項新產品、系統與服務,但我們必須提供的不僅是單一產品。在數位領域,你選擇的是平台,而不是產品。你選擇的是一家你願意長期信任的公司。數位牙科正由iTero掃描儀與Invisalign透明牙套等產品所驅動,而我們相信,我們的數位平台正在為牙科的未來奠定基礎。Align與我們的醫師合作夥伴正站在牙科史上最大成長領域之一的門檻上。我對這對我們業務的意義,以及我們在2020年及之後持續轉變笑容、改變人生並延續成長前景,感到非常振奮。

  • With that, I want to thank you again for joining the call. I look forward to updating you on our progress as the year unfolds. We'll see many of you at the Chicago Midwinter Meeting next month as well as industry and financial conferences throughout the year, including our Analyst Meeting on May 12 in New York City.

    那麼,我再次感謝各位參與本次電話會議。我期待在今年進展的過程中,向各位更新我們的進度。下個月我們也將在芝加哥Midwinter Meeting與各位中的許多人見面,並在全年各項產業與金融研討會上交流,包括5月12日在紐約市舉行的分析師會議。

  • Now I'll turn the call over to the operator for questions.

    現在我把電話交給接線員進行提問。

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from the line of Nathan Rich with Goldman Sachs.

    (接線員指示) 我們的第一個問題來自Goldman Sachs的Nathan Rich。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • Joe, maybe just to start on China. The revenue headwind that you guided to, I think, is kind of 60% or so of your kind of total China volume. Can you talk maybe just about what you've seen so far in January to kind of -- that you used to kind of inform your estimate of the case and revenue impact. And if we continue to see this play out, can you kind of help us think about how we should frame the impact going forward?

    Joe,或許先從中國談起。你們指引中提到的營收逆風,我想大約相當於你們中國總量的60%左右。你能否談談你們在1月迄今為止看到的情況——也就是你們用來支撐對病例數與營收影響估計的依據。如果我們持續看到事態發展,你能否協助我們思考,未來應該如何界定(frame)其影響?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Nate, I think we framed it as well as we can in the first quarter. I mean, and that's what we can see right now. I think our responsibility when you think about it is, we're through January right now. We can take a look at our order rates and we can responsibly make the prediction that John just did, that we've got 20,000 to 25,000 cases that we think we're going to be pressured on. The unfortunate part of this whole thing is, we say we're on the dark side of the moon right now because of the Chinese New Year and our order rates drop off to a point that you hardly see them. And it's not just now. It's been every year since. And since the government there has extended the holidays for another week or so and it could go on, we really don't have -- we just take our best guess on that 20,000 to 25,000. We're not ready to project. I'm not ready to project anything into the second quarter and the rest of the year. Remember, going back to SARS, I talked about -- I was involved in that with GE Healthcare, is that remember, it took 6 months from the initial infection rate, all the way to -- not that it ended, but it actually stabilized and things got back in gear again. So we know that it'd be more than the first quarter that will be impacted, but none of us are ready to give any kind of a forecast as to the extent of that.

    Nate,我想我們已在第一季把能說的都盡量說清楚了。我的意思是,這就是我們目前所能看到的。我認為我們的責任是——你想想看——我們現在已經走過1月。我們可以檢視我們的訂單率,並且負責任地做出John剛才所做的預測,也就是我們認為將受到壓力的病例數約為2萬到2萬5千例。整件事不幸的部分在於,我們說我們現在正處於「月球背面」的黑暗期,因為農曆新年期間我們的訂單率會下滑到幾乎看不到。而且不只是現在。每一年都是如此。再加上當地政府把假期又延長了大約一週,而且可能還會繼續延長,我們其實沒有——我們只能對那2萬到2萬5千例做出最好的猜測。我們還沒準備好做出推估。我也還沒準備好把任何推估延伸到第二季以及今年剩餘時間。回想SARS,我提到過——我在GE Healthcare時參與過那段期間——請記得,從最初的感染率開始到——不是說結束——而是實際上趨於穩定、事情重新回到正軌,花了6個月。所以我們知道受影響的不會只有第一季,但我們都還沒準備好就其影響程度給出任何形式的預測。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • That's fair. And then maybe just a question on the Americas GP growth. There's a nice acceleration in the quarter. Utilization also ticked higher. You've obviously put a lot of investment into that channel. Can you maybe just talk about some of the traction that you're seeing among the GP base that you serve?

    這很合理。接著想請教一下美洲地區 GP 成長的問題。本季有不錯的加速。使用率也略有上升。你們顯然在這個通路投入了很多資源。能否談談你們在所服務的 GP 客群中看到的一些進展與動能?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. There's multiple levers we pull in that sense, right? We have more of a segmentation around GPs today from a sales standpoint. You'll see that accentuated as we go into 2020. We have a product called iGO that it just fits the workflow aspect of GPs extremely well. Then you have to add to that the extra salespeople we put in last year. A lot of those salespeople were making GP calls because there's only so far you'd go for the orthodontic community. And the last part of that, we have a huge amount of increased advertising from a consumer standpoint. I read about the consumer hits for new interest in Invisalign which are pretty outstanding when you look at it from a year-to-year basis. So it's really all those variables we see are being put in place to help to drive that growth.

    是的。在這方面我們有多個槓桿可以運用,對吧?從銷售角度來看,我們現在對 GP 做了更細的分群。你們會在我們邁入 2020 年時看到這點更為明顯。我們有一個叫 iGO 的產品,它非常符合 GP 的工作流程。此外,還要加上我們去年增聘的額外業務人員。其中很多業務人員開始拜訪 GP,因為在矯正牙科社群那邊能拓展的範圍有限。最後一點,我們從消費者端大幅增加了廣告投放。我看到消費者對 Invisalign 的新興關注度(點擊/觸及)相當亮眼,若以年對年來看尤其明顯。所以我們看到,這些變數都已到位,來協助推動這項成長。

  • Operator

    Operator

  • Our next question comes from the line of Kevin Caliendo with UBS.

    下一個問題來自 UBS 的 Kevin Caliendo。

  • Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution

    Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution

  • Just a quick one on China. So a quick one on China. How is it impacting the training of the doctors in China? Obviously, it's impacting your revenues, but is it impacting the overall expansion of your business there as well so that as we think about the number of doctors and think about the number of dentists there that will be registered Invisalign users, how do we think about the impact this is going to have on that as well?

    關於中國我有個簡短問題。是關於中國的。這對你們在中國對醫師的訓練有什麼影響?顯然它影響了你們的營收,但是否也影響你們在當地業務的整體擴張?也就是說,當我們思考醫師數量、以及那邊會註冊成為 Invisalign 使用者的牙醫數量時,我們該如何看待這件事對這些指標的影響?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Kevin, honestly, it's a good question because that is a variable in the equation you have to think of. So right now, you can imagine when you have a contagion like this, you don't want a lot of people hanging out together. And Chinese government knows that, and we know it, too. Our training facilities are in Shanghai and also at Chengdu. Obviously, there's infection rates in those areas, but they're not like the major provinces that have been impacted so far. But my anticipation is, after the holidays, we'll just have to watch and see exactly what develops in the different provinces in China and what that means. If it's not a big issue in Shanghai or at Chengdu or whatever, obviously, we'll bring doctors in and train them. But we're not in a position to even guess on that right now. But it's a great question. It is a key variable. And as things develop, we'll certainly come back after the first quarter and let you know.

    Kevin,老實說,這是個好問題,因為這確實是你在方程式裡必須考量的一個變數。所以現在你可以想像,遇到這樣的傳染狀況,你不希望很多人聚在一起。中國政府知道這點,我們也知道。我們的訓練中心在上海,另外也在成都。這些地區當然也有感染率,但不像目前受影響最嚴重的那些主要省份。不過我預期,假期結束後,我們必須觀察中國各省份的發展情況以及其代表的意義。如果上海或成都等地不是大問題,當然我們就會把醫師帶進來訓練。但我們目前甚至無法對此做任何猜測。不過這確實是個很好的問題。它是一個關鍵變數。隨著情況發展,我們一定會在第一季之後再回來向你更新。

  • Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution

    Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution

  • And just one quick follow-up. As we talk about sort of expectations around margin expansion embedded in your 2020 guidance. Can you give us a little bit of apples-to-apples on what your -- if we were to sort of back into your non-GAAP gross margin or operating margin expansion, like what's sort of embedded in the non-GAAP side year-over-year?

    再追問一個簡短問題。當我們談到你們 2020 年指引中所隱含的利潤率擴張預期時,你能否用可比口徑(apples-to-apples)說明一下——如果我們要回推你們的 non-GAAP 毛利率或營業利益率擴張,non-GAAP 端年對年大概隱含了多少?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, Kevin, this John Morici. Yes, we would expect it to be slightly up, both on a GAAP and on a non-GAAP basis for operating margin as well as gross margin.

    是的,Kevin,我是 John Morici。是的,我們預期會小幅上升,無論是 GAAP 或 non-GAAP 口徑,營業利益率以及毛利率都會略為提高。

  • Operator

    Operator

  • Our next question comes from the line of John Kreger with William Blair.

    下一個問題來自 William Blair 的 John Kreger。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • John, first one is for you. Just to clarify that the full year '20 commentary that you gave us, does that reflect a weaker first quarter from China but the rest is up to us or does it not reflect the Q1 hit? Just wanted to clarify that.

    John,第一題問你。想確認一下你剛才對 2020 全年的評論:那是否已反映中國第一季較弱,但其餘部分就由我們自行推估?還是並未反映第一季的衝擊?只是想釐清一下。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • It's the latter. It does not reflect any impact from China.

    是後者。沒有反映任何來自中國的影響。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • No impact from China. Okay. That's helpful. And then, Joe, again, just sticking on the China theme. If we think about over the last year, the rates of growth that you guys have experienced in that region have been all over the place. From your perspective, what do you sort of view as sort of the new normal there in terms of once we get beyond the infection outbreak, is it 20%? Is it 50%? Do you have a updated view on it?

    沒有來自中國的影響。好的。這很有幫助。接著,Joe,還是延續中國的主題。如果回顧過去一年,你們在該地區的成長率起伏很大。從你的角度來看,一旦我們度過這次感染爆發之後,那邊所謂的「新常態」成長率會是什麼?是 20%?還是 50%?你對此有更新的看法嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • John, I don't. I mean because, obviously, we're in a storm right now and just trying to get through what that looks like. As I said in my script, if you think about as we came off the third quarter, we got a really good teen season. We didn't have as much of an adult pickup in the fourth quarter as we had hoped. But again, it was double-digit growth and still robust growth, but not the 50% to 60% that we've enjoyed in China for several years. So I'd say, John, I'd like to give that to you. I can't reliably give it to you now, but it's double-digit growth. We continue to make our investments. We continue to be excited about China. It's our second-biggest market. We don't think that's going to change, but we certainly got to get through this cloud before we can give you something definitive in that sense.

    John,我沒有。因為很明顯,我們現在正處於風暴之中,只是在努力撐過去並看清它會是什麼樣子。如我在講稿中提到的,如果你回想第三季結束後,我們迎來了一個非常好的青少年旺季。第四季成人端的回升沒有如我們所希望的那麼多。但即便如此,仍是雙位數成長,成長依然強勁,只是不再是我們過去幾年在中國享有的 50% 到 60%。所以我會說,John,我很想給你一個數字。但我現在無法可靠地給出;不過可以確定的是雙位數成長。我們會持續投資。我們仍對中國感到興奮。它是我們第二大市場。我們不認為這會改變,但在我們能給你更明確的說法之前,確實得先度過這片陰霾。

  • Operator

    Operator

  • Our next question comes from the line of Jon Block with Stifel.

    下一個問題來自 Stifel 的 Jon Block。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • So I'm going to throw out a couple of growth rates on China just trying to do some implied math. I mean, with 20,000 to 25,000 fewer cases in 1Q, it seems like you're implying that China is down 50% year-over-year in the first quarter in case volumes. And that would even be considering coronavirus is sort of not there for the entire quarter from a rev rec standpoint. So is that in the ballpark that we're seeing sort of that magnitude of a decel? And then maybe the follow-up to that first question would be, more importantly, what do you think about these cases? Are they lost? Are they delayed? Are they some sort of a combination of the 2?

    我想就中國丟出幾個成長率,試著做一些隱含的推算。我的意思是,第一季少了 20,000 到 25,000 個病例(cases),看起來你們是在暗示中國第一季的病例量年對年下滑 50%。而且這甚至還是在從營收認列角度來看,冠狀病毒並非整個季度都存在的情況下。所以我們看到的減速幅度大概就是這個量級嗎?然後也許針對第一個問題更重要的追問是:你們怎麼看待這些病例?它們是流失了?是延後了?還是兩者的某種組合?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Jon, this is John. I think you're in the ballpark, I think, when you look at what we see from China. I mean, certainly, last year was significant growth in Q1. And this year, obviously, impacted by the coronavirus. It's difficult to say from a -- are the cases lost or delayed and so on. They're certainly, for this time period, they're not happening. It's difficult for us to see afterwards, after this period of time to see whether those cases come back or not. But at least for the first quarter here, we're assuming that they're not going to come into the quarter.

    Jon,我是 John。我認為你的推估大致在合理範圍內,從我們看到的中國情況來看是如此。我的意思是,去年第一季的成長確實很顯著。而今年顯然受到冠狀病毒影響。至於病例是流失還是延後等等,這很難說。可以確定的是,在這段期間它們不會發生。而在這段期間之後,這些病例是否會回來,我們也很難判斷。但至少就第一季而言,我們的假設是它們不會在本季發生。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Okay. Got it. And then maybe just shift gears. I don't want everything lost on China. Joe, you highlighted, and I think for the first time, quantified the number of MAS and Invisalign First cases, pardon me. I think the summation was around 75,000 out of 450,000 teen cases for the year. So this has quickly become 15% to 20% of your teen cases. Maybe if you can just talk to that. Do you still see hyper-growth for those 2 offerings into 2020 and beyond? And maybe there's an update on palatal expansion as well.

    好的。了解。接著也許我們換個話題。我不希望所有焦點都落在中國。Joe,你剛才提到,而且我想也是第一次,把 MAS 和 Invisalign First 病例數量量化了,不好意思。我記得加總大約是全年 45 萬件青少年病例中的 7.5 萬件左右。所以這很快就變成你們青少年病例的 15% 到 20%。也許你可以談談這點。你是否仍然看好這兩項產品在 2020 年及之後的超高速成長?另外也想請你更新一下腭擴張(palatal expansion)的進展。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Jon, yes, I'm really excited about the MAS growth when you see that. And remember, MAS, too, it's kind of age contained. It's a growth aspect between like 10 years old and 12.5 years old where that really fits. But when you take MAS and you combine that with First, that is about 20% to 25%, including palate expansion of the teen marketplace. So the idea that, that's 15% to 20% of our teen cases as you talked about matches up pretty well in the sense of what we're seeing in the marketplace overall. I do think you'll continue to see this hyper-growth out there. It is a great solution. I mean, look at teen first and how it works. You don't see it, Jon, but we continue to improve MAS all the time. We learn about anchorage on back molars and certain kinds of teeth and whatever. We program those things. We have silent releases. But piece by piece, we get better at being confident in moving those Class II things forward. So overall, we're excited about it. I'm confident about the technology.

    Jon,是的,看到 MAS 的成長我真的很興奮。而且要記得,MAS 也算是有年齡區間限制。它主要適用於大約 10 歲到 12.5 歲之間的成長階段,最符合這個需求。但當你把 MAS 與 First 結合來看,連同腭擴張在內,約占青少年市場的 20% 到 25%。所以你剛才提到它占我們青少年病例的 15% 到 20%,就整體市場我們看到的情況而言,吻合度相當高。我確實認為你會持續看到這些產品的超高速成長。這是一個很棒的解決方案。我的意思是,看看 teen first 以及它的運作方式。你看不到的是,Jon,我們一直在持續改進 MAS。我們學到如何在後方臼齒、某些類型的牙齒等方面做錨定(anchorage)。我們把這些內容寫進程式。我們也會做無聲版本更新(silent releases)。但一點一滴地,我們在把那些 II 類(Class II)問題往前推進的移動上,越來越有把握。所以整體而言,我們對此很興奮。我對這項技術很有信心。

  • Lastly, on the palate expansion piece, we know how to make this. We have the right kind of software to develop it. The trick is finding something that you can actually scale from a manufacturing standpoint and get consistent properties with it. And I feel that we've been closing in on that rather fast. So we'll give you more of an update as we go into the investors conference in June -- I mean, in May and more specificity around that kind of a launch date.

    最後,關於腭擴張這一塊,我們知道怎麼做。我們也有合適的軟體來開發它。關鍵在於,從製造角度要找到一個能真正規模化生產、且能保持一致性特性的方案。我覺得我們在這方面正相當快速地逼近可行解。所以等到 6 月的投資人會議——我是說 5 月——我們會再提供更多更新,以及更明確的上市時程細節。

  • Operator

    Operator

  • Our next question comes from the line of Richard Newitter with SVB Leerink.

    下一個問題來自 SVB Leerink 的 Richard Newitter。

  • Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

    Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

  • Joe, I have 2 for you. Just going back to your comment on your experience with SARS, the last time and the impact on the business you were running there at GE, can you maybe just give a little bit more color on what's the definition of stabilization and kind of maybe just talk through some of the visibility that was able to come into focus and how that happened over that 6-month time period and then I have a follow-up.

    Joe,我有兩個問題。先回到你提到上次 SARS 的經驗,以及當時對你在 GE 所負責業務的影響,你能否再多補充一些細節:你所說的「穩定」定義是什麼?另外也請談談在那 6 個月期間,哪些可見度逐步變得清晰、以及是如何發生的。之後我還有一個追問。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Rich, it's really interesting. As I say, when I talk about stabilization, it means infection rate. When you start to get to that plateau about not an increase in infection rate, but a decrease, and you'll see that. That's kind of the deceleration. And that indicates that it's kind of under control. Again, what I learned in 2003 about China is, and I think in the Western world we miss this sometimes. It's how much influence the overall government influences there. You can see they change holidays. They lock down cities. They take drastic measures to try to deal with these things. It's something that's really unheard of from a Western world standpoint. And I think we kind of have to respect that. That it's a society that will respond to these kind of things in a way that we're not necessarily used to, which is actually good for the population because they're just trying to isolate it and contain that thing because depending -- that virus hasn't been quantified yet with exactly its infection rate, meaning how many people are infected per person that's infected, but the numbers are jumping around but this is in the area of SARS. And so I think the best proxy we can have right now is a SARS side. So that's the 2 things. Just one is, when it plateaus, when fewer people are being infected and you see that curve start coming down. And then secondly is, how fast the Chinese government will move. And that's why we're staying close with what's going on there and just staying behind the government and trying to support their actions. Okay, Rich?

    是的。Rich,這真的很有意思。如我所說,我講的「穩定」指的是感染率。當你開始看到感染率不再上升、而是下降,並且進入那個平台期時,你就會看得出來。那就是所謂的減速。而這表示情況大致受到控制。另外,我在 2003 年對中國學到的一點是——我想西方世界有時會忽略——就是整體政府影響力有多大。你可以看到他們會調整假期。他們會封鎖城市。他們會採取非常激烈的措施來處理這些事情。從西方世界的角度來看,這幾乎是聞所未聞的。我認為我們必須尊重這一點。那是一個社會,會以我們不一定習慣的方式來回應這類事件,而這其實對民眾是有利的,因為他們就是要隔離並控制它;因為——這個病毒的感染力尚未被精確量化,也就是每位感染者會傳染給多少人——數字仍在跳動,但大致落在 SARS 的範圍附近。

  • Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

    Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

  • Okay. That's helpful. Okay. Just a follow-up here on -- I appreciate the operating margin guidance, excluding the China factors here. But let's just say there is some extended impact moving through the year. How are you thinking about your approach to operating margins if there were to be kind of an extended shortfall in revenues from that region? And would you kind of go full blast on the spend or is there a target that you'll kind of look to on preserving leverage?

    好的。這很有幫助。好。接著追問一下——我理解你們在排除中國因素後所提供的營業利益率指引。但假設影響延續並貫穿全年,如果該地區營收出現較長時間的缺口,你們會如何思考營業利益率的因應策略?你們會在支出上全力投入,還是會設定某個目標來維持營運槓桿?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Rich, this is John. It's probably too early to tell that now. I mean, like we said, we're kind of in the dark side right now of the extended Chinese New Year. We'll see how things progress as we come out and make that assessment. I mean, as we've talked about a number of times in our business, there's a lot of different levers that we can pull or not pull based on the conditions that are going on in a particular market, and we would assess that as well with China.

    Rich,我是 John。現在判斷可能還太早。我的意思是,如同我們說的,我們目前仍處在中國農曆新年延長期間的「黑暗期」。等情況逐步明朗後,我們會再觀察進展並做出評估。我的意思是,正如我們在業務上多次談到的,我們有很多不同的槓桿可以視特定市場的狀況選擇拉動或不拉動,而對中國我們也會同樣評估。

  • Operator

    Operator

  • Our next question comes from the line of Matthew O'Brien with Piper Sandler.

    下一個問題來自 Piper Sandler 的 Matthew O'Brien。

  • Matthew Oliver O'Brien - MD and Senior Research Analyst

    Matthew Oliver O'Brien - MD and Senior Research Analyst

  • Just a couple here. One was asked a little bit earlier just about the deferral of these cases. I mean, if they're locking everybody down in China at this point, it's not like they're going to be getting brackets and wires. So I'm just trying to figure out why this wouldn't come back in eventually? And then if it were to come back in, say, in a Q4 time frame or something like that, could you do upwards of 50,000 cases in a quarter? So like all of this would come running back to you fairly quickly if the all clear was signaled?

    我這邊有幾個問題。其中一個稍早有人問到,就是關於這些病例的遞延。我的意思是,如果他們現在在中國把所有人都封控起來,也不可能去裝牙套托槽和鋼絲。所以我想弄清楚,為什麼這些需求不會在之後終究回補?另外,如果之後回補,例如在第四季之類的時間點,你們單季能做到超過 5 萬件病例嗎?也就是說,一旦發出全面解除的訊號,這些量是否會相當快地全部回流到你們這邊?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Matt, could we do 50,000 cases? Yes. I mean, we have capacity. We have both treatment capacity and we have bleed off capacity, obviously, through Mexico and Costa Rica if we were overwhelmed in China and what we have there, too. But Matt, my experience in this business is that things don't happen like that. That you don't get this kind of a bow wave that comes after something like this. And so it's not that you lose those cases. From an adult standpoint, they just get pushed out into the future, but they don't come back to you all at once. It's just latent demand. The only exception I would make to that, that I would guess that the teen season because teens are kind of timed based on their age, that you have a little more of what I call bolus effect there. You have a bow wave that you really capitalize on teens, but it wouldn't occur that way with adults.

    Matt,我們能做 50,000 個病例嗎?可以。我的意思是,我們有產能。我們同時有治療產能,也有分流產能;顯然,如果我們在中國以及我們在那裡的產能被壓垮,我們可以透過墨西哥和哥斯大黎加來分流。但 Matt,我在這個行業的經驗是,事情不會那樣發生。也就是說,在這種事件之後,不會出現這種「浪頭」式的需求堆積隨後一次湧現。所以並不是你會失去那些病例。從成人的角度來看,它們只是被推遲到未來,但不會在某個時間點一下子全部回到你這裡。那只是潛在需求。我唯一會例外看待的是,我猜青少年季因為青少年在某種程度上是依年齡時點安排的,所以會有我所說的「脈衝效應」更明顯一些。青少年會出現你可以真正把握的需求浪頭,但成人不會以那種方式發生。

  • Matthew Oliver O'Brien - MD and Senior Research Analyst

    Matthew Oliver O'Brien - MD and Senior Research Analyst

  • Okay. Can you give us -- so it's fair to assume that this is not lost revenue, it will come back at some time. Can you give us any sense for the split between the 2, teen versus adult over in China?

    好的。你能否說明一下——所以可以合理假設這不是流失的營收,它會在某個時間點回來。你能否讓我們大致了解一下在中國那邊,青少年與成人這兩者之間的占比?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No. At this point in time given what we're seeing over there, I can't even guess that. If you're asking for historical splits, I don't think we've shared that data in the past. And just know that our third quarter is always our biggest quarter in China. And it's the biggest because it is teen season. So if you take that look, historically, you'd see what those numbers look like on adult versus teen.

    不能。就目前我們在那邊看到的情況而言,我甚至無法猜測。如果你問的是歷史占比,我不認為我們過去分享過那個數據。但你只要知道,我們在中國的第三季一向是最大的季度。之所以最大,是因為那是青少年季。所以如果你從那個角度回看歷史,你會看到成人與青少年的數字大概是什麼樣子。

  • Matthew Oliver O'Brien - MD and Senior Research Analyst

    Matthew Oliver O'Brien - MD and Senior Research Analyst

  • Got it. One quick one for John, just on gross margin. It's come down over the last kind of 3 years to the low 70s in 2019 and a lot of moving parts here, but how do we think about that metric going forward? Are we kind of getting close to the bottom on that metric or should we expect more kind of annual erosion of that metric?

    了解。給 John 一個很快的問題,關於毛利率。過去大約 3 年毛利率一路下滑,到 2019 年落在 70% 出頭,這裡面有很多變動因素,但我們該如何看待這個指標未來的走勢?我們是否已經接近這個指標的底部,還是應該預期它每年還會繼續有些下滑?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Well, I think you saw that our gross margin improved 60 basis points in Q4 from Q3. And we would look into the future to expect that with the cases that we do, sometimes more difficult versus even the noncomprehensive cases, we know how to drive that gross margin, and we'd expect to see improvement in 2020 and beyond.

    嗯,我想你看到我們的毛利率在第四季相較第三季改善了 60 個基點。展望未來,隨著我們所做的病例中,有時會有較困難的病例(相較於一般的非全口病例),我們知道如何去拉動毛利率,我們預期 2020 年及之後會看到改善。

  • Operator

    Operator

  • Our next question comes from the line of Steve Beuchaw with Wolfe Research.

    下一個問題來自 Wolfe Research 的 Steve Beuchaw。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • I wanted to try to maybe put a rosier lens potentially on China for just a second so we can consider the possibility that things do resolve. One is -- and sorry if I missed this, but did you give China growth for the fourth quarter? And then the second part of it is, if this ends up isolated to Wuhan or the provinces surrounding Wuhan, how does that change your view on the impact to the business?

    我想先用比較樂觀的角度看一下中國,讓我們考慮事情可能會解決的情境。第一個是——抱歉如果我漏聽了,你們有提供第四季中國的成長率嗎?第二個部分是,如果最後這件事只侷限在武漢或武漢周邊省份,這會如何改變你們對業務影響的看法?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Steve, it's Joe. It would obviously change it because now you segment what the issue is in China, but I don't have a guess in a sense of what that would mean. I mean, when you think about it, obviously, Shanghai is a big part of our business and more north of that Beijing is, too. I'd say the coastal provinces or whatever have always been pretty big. So I think a comment would be, if it's just isolated to Wuhan or generally isolated to Wuhan, the effect won't be as dramatic, but I can't -- I really can't quantify it, Steve. And I find it kind of surprising that not that the infection rate is going to reach the other provinces the way it has Wuhan, it's just the Chinese government will take the same steps there to make sure that whatever infection that they do have in those regions don't end up being like Wuhan. That make sense?

    Steve,我是 Joe。那當然會改變,因為你就能把中國的問題做區隔,但我沒有一個可以猜測其意涵的數字。我的意思是,當你去想,顯然上海是我們業務很大的一部分,往北的北京也是。我會說沿海省份之類的一直都占比很大。所以我的評論會是,如果真的只侷限在武漢或大致侷限在武漢,影響就不會那麼劇烈,但我無法——我真的無法量化,Steve。而且我覺得有點意外的是,並不是說感染率會像在武漢那樣擴散到其他省份,而是中國政府會在那些地方採取同樣的措施,確保那些地區即便有感染,也不會演變成武漢那樣。這樣說有道理嗎?

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • It makes a lot of sense. And I'm sorry, did you give a China growth rate for 4Q?

    非常有道理。抱歉再確認一下,你們有提供第四季中國的成長率嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • No. We didn't, Steve. It's similar growth that we saw in Q3.

    沒有。我們沒有提供,Steve。成長幅度與我們在第三季看到的相近。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • Okay. Perfect. And then, John, just a couple of quick ones for you and then I'll drop back in the queue. One is, are you willing to give folks a sense for how much of the benefit on the margins in 2020 there is tied to the wind-down of the Netherlands facility or some of the legal expenditures winding down? And then can you give a sense for what your assumption is for pricing year-on-year and the outlook for 2020. I really appreciate the color.

    好的。完美。接著 John,我再問你兩個很快的問題,然後我就回到隊列後面。第一個是,你是否願意讓大家了解一下,2020 年毛利率改善的好處中,有多少是來自荷蘭廠的逐步關閉,或部分法律支出逐步下降?另外,你能否說明一下你們對年度同比定價的假設,以及 2020 年的展望?非常感謝你提供的細節。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. When you look at some of that litigation and some of those entity restructuring programs, it impacted us in 2019 by about 1 point of op margin. So essentially, that's a benefit for us in 2020, and that's part of our expansion. But when we look at the expectations for 2020 and a comparison versus 2019, we would expect margin expansion, whether you're using GAAP or non-GAAP based on the leverage and the investments that we're making.

    可以。當你看一些訴訟以及一些法人實體重組計畫時,它們在 2019 年對我們的營業利益率影響大約是 1 個百分點。所以基本上,這在 2020 年就會成為我們的利多,也是我們擴張的一部分。但當我們看 2020 年的預期並與 2019 年比較時,我們預期不論你用 GAAP 或 non-GAAP 口徑,基於營運槓桿以及我們正在進行的投資,都會看到利潤率擴張。

  • Operator

    Operator

  • Our next question comes from the line of Brandon Couillard with Jefferies.

    下一個問題來自 Jefferies 的 Brandon Couillard。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Joe, I don't have a question about China. Actually, I want to talk about the U.S. Curious if you've seen any or just curious to get your latest views around just the competitive environment between DTC and in the office. And also noticed you put Frank Quinn in a new role in terms of Head of the U.S., curious about the rationale behind that and whether that's a reflection of a bigger focus on perhaps the DSO channel?

    Joe,我沒有關於中國的問題。其實我想談談美國。我想了解你是否看到任何情況,或想聽聽你最新的看法:關於 DTC 與診所端之間的競爭環境。另外也注意到你讓 Frank Quinn 擔任新的職務,成為美國負責人,我想了解背後的理由,以及這是否反映你們可能更聚焦於 DSO 通路?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I think, Brandon, that's a good question. Actually, that's a good, deep question. First of all, I mean, you saw our growth in the Americas for the fourth quarter. It's good, accelerating in the GP channel and good progress in the ortho channel. So obviously, I feel good about -- I talked about on the previous caller in the sense of the investments we've made in salespeople and advertising products and all that we have in those different channels. And we look at that going forward, we feel good about that capability.

    Brandon,我覺得這是個好問題。其實這是個很好的、很深入的問題。首先,你也看到我們在美洲地區第四季的成長。在 GP 通路的成長不錯且在加速,在矯正通路也有良好進展。所以顯然我對——我在上一位提問者那裡也談到過,從我們在銷售人員、廣告產品以及我們在不同通路所做的各項投資來看,我對此感到樂觀。而展望未來,我們對這項能力也很有信心。

  • From a DTC standpoint, we've always stuck with what we said. I mean, we know that DTC will go after some of the same patients we do, but we haven't necessarily felt an impact in that sense. And you see us pushing hard in the sense of our product and portfolio to go after that. We talked about 100 million patients that we think want treatment from an orthodontic standpoint in North America.

    就 DTC 而言,我們一直堅持我們所說的。我的意思是,我們知道 DTC 會爭取到一些與我們相同的患者,但我們不一定覺得在那個意義上受到影響。而你也看到我們在產品與產品組合方面積極推進,以爭取那部分需求。我們談到過,在北美從矯正角度來看,我們認為有 1 億名患者想要接受治療。

  • Other competitors, honestly, they're out there. I can't say that we've made any price moves against them. We haven't necessarily felt that we have lost any significant volume in any consistent way. And so I don't have anything different to report from that standpoint than I did the previous quarters when we had that kind of discussion.

    其他競爭對手,坦白說,他們確實在市場上。我不能說我們有針對他們做出任何價格調整。我們也不一定覺得自己以任何一致性的方式流失了任何顯著的量。因此,從這個角度來看,我沒有什麼不同於前幾季我們進行那類討論時可報告的內容。

  • I think when you're hearing about that too, Brandon, it's what -- I think we've been consistent for the last 2 years. And I talked about at the end of my script about this digital platform, there's a lot of work you have to do to compete in this marketplace. It's not like just I could probably produce a plastic aligner and then I can have a material difference in how Align is effective in the marketplace. There's just so many things you got to be good at in this business from a logistics standpoint, from a manufacturing standpoint, your digital platform, how it serves consumers and what it does with docs. You've got to be able to play really well in multi-dimensions. And I'm not saying that none of our competitors will reach that. They're just not at that scale right now but I think that it's made a tremendous difference to us in any way.

    Brandon,我認為當你也聽到那些說法時,我們在過去兩年其實一直很一致。而且我在講稿最後提到這個數位平台:要在這個市場競爭,你必須做很多工作。並不是說我大概做出一個塑膠隱形牙套,就能在 Align 在市場上的有效性方面產生實質差異。在這個業務裡,你需要在很多事情上都做得很好:從物流面、製造面、你的數位平台、它如何服務消費者,以及它如何與醫師端互動。你必須能在多個維度上都表現得非常出色。我不是說我們的競爭對手都不會達到那個程度。只是他們目前還沒有那樣的規模,但我認為這已在各方面為我們帶來了巨大的差異。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Then the question about...

    接著是關於……的問題。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • On Frank, I'm sorry, John just reminded me. On Frankie, look Frank's a great commercial leader, right? I know he's associated with DSOs and he helped to put us on the map with DSOs with his leadership. But overall, Frank, he came here with good external experience from a sales and dental standpoint. He's really helped the business that way. And I thought he's a perfect pick for us to really help to, I'd say, to really help us not just extend what we do, but he'll put a lot of focus from a commercial standpoint in our business. So we're excited about Frank. He has a good relationship with Simon, who has great experience from Europe also and taking some best practices there and implementing them. And so we're excited about Frank and Simon and broadly, the North American team.

    關於 Frank,不好意思,John 剛提醒我。關於 Frankie,你看,Frank 是一位很出色的商業領導者,對吧?我知道他與 DSO 有所關聯,而且在他的領導下,他幫助我們在 DSO 領域打開知名度。但整體而言,Frank 來到這裡時,在銷售與牙科領域具備很好的外部經驗。他確實在這方面大幅協助了業務。我認為他是非常適合的人選,能真正幫助我們——我會說,不只是延伸我們正在做的事,他也會從商業面在我們的業務中投入大量焦點。所以我們對 Frank 感到很振奮。他與 Simon 的關係很好;Simon 也有來自歐洲的豐富經驗,能把那邊的一些最佳實務帶進來並加以落地。因此,我們對 Frank 和 Simon,以及更廣泛的北美團隊都感到很期待。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Then a question about Invisalign Moderate. Any early feedback you can share on that rollout? Is an international launch in the works? And just curious about your thoughts in terms of whether you might see more trade up from Invisalign Lite rather than -- more so than trade down, perhaps, from a more comprehensive case for those patients?

    接著是一個關於 Invisalign Moderate 的問題。你們能分享一些關於這次推出的早期回饋嗎?是否正在規劃國際上市?另外也想請教你們的看法:你們是否可能看到更多患者從 Invisalign Lite 升級(trade up),而不是——或許相較之下——從更全面的療程方案降級(trade down)?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. I think we haven't actually documented much trade up from Lite in that product line as most of it had been trade down from Comprehensive. But remember, when you trade down on this product line, it still has a gross margin, so it's accretive to our business and not decretive in that sense. So we're allowing more choice for our patients, allowing more choice for our doctors, but we're not doing this to an extent that it really hurts our operating profit.

    是的。我認為我們其實尚未在那條產品線中記錄到太多從 Lite 升級的情況,因為大多數是從 Comprehensive 降級而來。但請記得,當你在這條產品線上做降級時,它仍然有毛利,因此對我們的業務是增益(accretive),而不是稀釋(decretive)。所以我們是在為患者提供更多選擇、為醫師提供更多選擇,但我們並不是做到會真正傷害我們營業利益的程度。

  • Operator

    Operator

  • Our next question comes from the line of Jeff Johnson with Robert W. Baird.

    下一個問題來自 Robert W. Baird 的 Jeff Johnson。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Joe, I missed the prepared remarks, so I'll go back to the transcript on that. But just a question, one other on China. And maybe you addressed it, but are you seeing any bleed outside of China, any of the tangential markets where patients are also hesitant to go to hospital settings, dental settings, dental office settings, things like that, any early indications of anything brewing like that?

    Joe,我錯過了事先準備的發言,所以我會回去看逐字稿。不過我還有一個關於中國的問題。也許你已經提到了,但你們是否看到任何影響外溢到中國以外的情況——例如一些周邊市場,患者也開始對去醫院環境、牙科環境、牙科診所等有所顧慮?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No, Jeff, nothing like that so far. We haven't seen anything anywhere around the world in that sense. Hong Kong has been kind of locked down since the protest or whatever so it's hard to get a signal out of there one way or another, but Taiwan, Korea, some of the neighboring countries, Southeast Asia, we haven't seen anything.

    沒有,Jeff,到目前為止沒有那樣的情況。就這個層面而言,我們在全球任何地方都還沒看到。香港自從抗議或其他事件以來就有點處於封鎖狀態,所以很難從那裡得到明確訊號,但台灣、韓國、一些鄰近國家、東南亞,我們都沒有看到任何情況。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • All right. That's helpful. And then at the GP Summit late last year, Joe, you made a big effort, I thought, to kind of at least put in, in people's head the idea of around a $2,500 price point, $3,000 price point, things like that. We've anecdotally been hearing some guys dropping their prices there to compete more against the DTCs. We did some survey work, though, and didn't find that at all. In fact, I think GPs and orthos both thought their price points that they'd charge patients going up over the next 12 and 24 months. Just what are you hearing on a more consolidated basis? Are these docs willing to kind of go aggressively after this lower comprehensive or noncomprehensive market and use some of your newer product to do that and really get after that 100 million patient population in North America?

    好。這很有幫助。另外,Joe,在去年年底的 GP Summit 上,我覺得你很努力地至少把大約 2,500 美元、3,000 美元這樣的價格點概念放到大家腦中。我們零星聽到有些醫師為了更直接與 DTC 競爭而下調價格。不過我們做了一些調查,卻完全沒有發現這種情況。事實上,我認為全科牙醫(GP)和矯正醫師(ortho)都覺得他們未來 12 到 24 個月向患者收取的價格點會上升。你們更整體、彙總地聽到的是什麼?這些醫師是否願意更積極地切入這個較低價的全面或非全面市場,並使用你們一些較新的產品來做到這點,真正去觸及北美那 1 億名患者族群?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Jeff, it's funny -- not funny, but it's really interesting. There's a lot of noise out there, right? And it's just your question is, how do you pull signal from noise out of this whole thing? And what we feel is, obviously, there's a lot of doctors, both GPS and orthos. There is a segment, a significant segment of them that see really a clinical build, meaning you don't have to do a complete bite reconfiguration. You can responsibly move the anterior teeth to give a good smile without having to move molars and other aspects of what's going on. Those doctors that are seen as progressive is, hey, maybe I'll fix the anterior teeth for a lower price and then move to a full bite correction at some point in time the patient wants to go. We see both orthodontists and GPs, a certain segment of them really engaging in that sense.

    是的。Jeff,這很有意思——不是好笑,但確實非常有意思。外面有很多雜音,對吧?而你的問題其實是:在整件事裡,你要如何從雜音中提取訊號?我們的看法是,顯然有很多醫師,不論是全科牙醫(GP)或矯正醫師(ortho)。其中有一個族群——而且是相當大的族群——看到的是一種臨床上的建構,也就是你不必做完整的咬合重建。你可以在負責任的前提下移動前牙,讓笑容更好看,而不必移動臼齒或處理其他相關面向。那些被視為較進步的醫師會想:嘿,也許我可以用較低的價格先把前牙調整好,之後如果患者想要,再在某個時間點進一步做完整的咬合矯正。我們確實看到矯正醫師與全科牙醫中,有一部分人以這種方式積極投入。

  • So we feel confident there's enough doctors out there that want to hit this kind of a price point, and we'll do it in a very efficient way. Some of them look at it doing with maybe 2 or 3 touches with a patient rather than constant touches every few weeks and using remote monitoring and those kind of things to see how patients are going. So we actually feel that there are doctors out there with a limited product that will engage in that sense and be able to go after these, what we'd call price-sensitive DTC patients who are looking for just really an aesthetic correction and not a bite correction.

    因此我們有信心,市場上有足夠多的醫師希望達到這樣的價格點,而我們也會以非常有效率的方式來做到。其中一些人會用可能只需要與患者接觸 2 到 3 次的方式,而不是每隔幾週就持續接觸,並搭配遠端監測等方式來觀察患者的進展。所以我們其實認為,確實有醫師會用一個較受限的產品來參與其中,並能夠去爭取我們所稱的價格敏感型 DTC 患者——他們只是在尋求美觀上的矯正,而不是咬合矯正。

  • Operator

    Operator

  • Our next question comes from the line of Steven Valiquette with Barclays.

    下一個問題來自 Barclays 的 Steven Valiquette。

  • Steven James Valiquette - Research Analyst

    Steven James Valiquette - Research Analyst

  • My China questions also have been addressed. I'm going to go non-China for a moment. Just a question on the total ASPs. For the portion of ASP that was down sequentially due to the promotional discounts that you alluded to, just curious for more color around that, whether that's related to maybe higher volumes being achieved by individual practitioners, kind of like what happened in mid '18 that nobody probably wants to relive if they can help it? Or is this perhaps related to maybe a greater mix of DSO business, maybe more discounts for groups, maybe less related to individuals? Just more color around the discount that you alluded to.

    我關於中國的問題也已經被回答了。我先暫時談一下非中國的部分。我想問的是整體 ASP(平均銷售價格)。就 ASP 中那一部分因你們提到的促銷折扣而較前一季下降的原因,我想了解更多細節:這是否與個別執業醫師達到較高量而觸發的情況有關——有點像 2018 年年中發生過、大家可能都不想再經歷一次的那種狀況?或者這可能與 DSO 業務占比提高有關,例如對團體給予更多折扣、與個人較無關?想請你們就剛才提到的折扣再多補充一些說明。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I think, Steve, as you look at it, we run promotions on a regular basis to be able to drive volume, drive behavior. We see a mix effect of that as well where in Q3 there was maybe more ortho cases and in Q4 more proportionally GP cases. But as we said, as I said really throughout 2019, we expected our ASPs to be relatively flat throughout the year, notwithstanding FX. And if we looked at where things were a year ago, we're up $5. And if you look at the FX impact to that, it was a negative $15. So you're going to have puts and takes as you go through the quarters, but we saw relative consistency throughout the year on our ASPs.

    是的。我認為,Steve,從你的角度來看,我們會定期推出促銷活動,以帶動出貨量、帶動行為改變。我們也看到由此帶來的組合效應,例如第三季可能有較多矯正(ortho)病例,而第四季則相對更多一般牙科(GP)病例。但正如我們所說的,也如我在2019年整年反覆提到的,我們預期全年ASP(平均銷售單價)大致持平,不考慮匯率(FX)因素。如果我們回頭看一年前的水準,我們上升了5美元。而如果你看匯率對此的影響,則是負15美元。因此在各季度之間會有此消彼長的因素,但我們看到全年ASP整體上相對一致。

  • Operator

    Operator

  • Our next question comes from the line of Michael Ryskin with Bank of America.

    下一個問題來自美國銀行(Bank of America)的Michael Ryskin。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • The same, a lot of the China questions have been sort of fleshed out. I want to follow up on Steve's question just now and sort of, how do you think about that moving forward, the ASP component, as we move through 2020? You highlighted some of the moving pieces you had in 2019 and historically. And you've also got a shifting portfolio mix, a shifting geographic mix, especially with some of the China events going on. Just want to get a sense of how you're thinking about both discounts, promotions, the Advantage Program and the mix shift evolving over the next couple of years. So net-net, how do you envision ASPs trending down?

    同樣地,關於中國的許多問題已經大致被釐清了。我想接續剛才Steve的問題,並請教你們往前看時,對ASP這個構成要素在2020年推進過程中的看法。你們提到2019年以及過往歷史上有一些變動因素。同時你們的產品組合也在變、地理組合也在變,尤其是在一些中國事件發生的情況下。我想了解你們如何看待折扣、促銷、Advantage Program(優勢計畫)以及組合轉移在未來幾年的演變。總體而言,你們如何預期ASP會呈現下行趨勢?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. It's a good question, Michael. I mean, you think of it, just think of them separately for once and then will go together. So if you look at it separately, if you look at the Comprehensive product, relatively consistent. There's not going to -- from a promotion standpoint, everything else you would expect, consistency in those ASPs, same way from a noncomprehensive product. But when you see the interaction between the 2, as noncomp grows faster, you could see ASPs to be flat to be slightly down as a result of that mix. And as we said, and as we saw in the fourth quarter, where ASPs, even if it's at a lower ASP, it still comes with a higher gross margin. And we saw that in the fourth quarter. We expect that going forward. So when we look to the future, ASPs, of course, get the headlines, but we're really focusing on driving that gross margin and operating margin.

    是的。這是個好問題,Michael。我的意思是,你可以先把它們分開來看一次,然後再把它們合在一起看。如果分開來看,Comprehensive(全套)產品相對一致。從促銷角度來看——以及其他你會預期的因素——這些ASP應該會維持一致;非Comprehensive產品也是同樣。但當你看到兩者之間的互動時,隨著非Comprehensive成長更快,因為組合因素,你可能會看到ASP持平到略微下滑。而正如我們所說、也如我們在第四季所看到的,即使ASP較低,它仍然伴隨更高的毛利率。我們在第四季看到了這點。我們預期未來也會如此。因此當我們展望未來時,ASP當然會成為媒體焦點,但我們真正聚焦的是推動毛利率與營業利益率。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • Great. And quick one, if I may, as well on the scanner segment, on the iTeros. Strong end to the year, but still sort of not nearly at the same pace you had early. And I realize part of that is the stacked comps, but there's also been a lot of noise in the market with some other competitive entrants throughout 2019. Can you talk about anything you're seeing in iTero, if it's tied to some of your DSOs where you've sort of exhausted the pool of the installs that you had when you signed on board with them or if it's something from the competitive landscape you're seeing?

    很好。另外我想再快速問一個,關於掃描器(scanner)業務、iTero。年底表現強勁,但整體節奏仍然不像你們早期那樣快。我知道部分原因是比較基期(stacked comps),但2019年市場上也有不少雜音,因為有其他競爭者進入。你能談談你們在iTero看到的情況嗎?例如是否與你們的一些DSO(牙科服務組織)相關——你們在與他們合作簽約時原本可安裝的機會池是否已經消化得差不多——或是你們在競爭態勢上看到的影響?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I still felt great about the growth in the iTero business for the year, right, was up 38%. And you're right. I mean, when you look at the capital equipment market and any medical business, right, the fourth quarter is usually the biggest one that people are looking at. What they're going to do from a CapEx standpoint, they buy. So it was a tough comparison year-over-year, but still growing 20%.

    我仍然對iTero業務今年的成長感到非常滿意,對吧,全年成長了38%。而你說得沒錯。我的意思是,當你看資本設備市場以及任何醫療業務時,第四季通常是大家最關注的一季。他們在資本支出(CapEx)方面要做什麼,就會去採購。所以同比比較是很艱難的,但我們仍然成長了20%。

  • I think the best way to think about this, Michael, there's competition out there. We feel really good about our digital platform that iTero represents, how it competes against any scanner really out there. And you see that it's doing well on restorative, too, as well as from an orthodontic standpoint. So we think we're really competitive. But as you -- I think back to your question is like, how do you model that thing going forward? I think you model that at our 20% to 30% growth rates that we have given you for our business in general. And that's what we've done through the many years we've had iTero so far is keeping that range. Sometimes we've been outside that range, but on the upside or whatever. But long term when you model it, think of 20% to 30% and a significant amount of that being some services revenue, too, that really helps in that.

    Michael,我認為最好的理解方式是:市場上確實有競爭。我們對iTero所代表的數位平台非常有信心,無論面對市面上任何掃描器,它的競爭力都很強。你也看到它在修復(restorative)領域表現良好,同時在矯正領域也是如此。所以我們認為我們非常具競爭力。但回到你的問題:你要如何對未來做建模?我認為你應該用我們給出的、整體業務20%到30%的成長率區間來建模。而這也是我們擁有iTero這些年來一直維持的區間。有時我們會超出該區間,但通常是向上超出或其他情況。但長期建模時,請以20%到30%來看,其中相當一部分也會來自服務收入,這對整體也很有幫助。

  • Operator

    Operator

  • Our next question comes from the line of Erin Wright with Crédit Suisse.

    下一個問題來自瑞士信貸(Crédit Suisse)的Erin Wright。

  • Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

    Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

  • Follow-up on iTero. I guess what's the early feedback on the 5D scanner and how should we think about the overall opportunity on that front?

    追問iTero。我想請問對5D掃描器的早期回饋如何?以及我們應該如何看待這方面的整體機會?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • The doctor feedback, Erin, it's Joe, on the 5D scanner has really been great. I mean, the ones that really use it to scan every patient when they come in, they're picking up caries or cavities at a rate that are almost 2x of what they can actually visually see or see through an X-ray, and that's driven a lot of new business through those docs. And so a lot of this information comes in EMEA, obviously, outside the United States because the FDA hasn't approved that yet. So we see these near-infrared technologies that were being used to see cracks in teeth and caries in teeth as really helping from a cash flow standpoint from a doctor in the cases they're seeing. And secondly, it's helping patients in that sense to be able to identify issues that you can get at a little more proactively before they really become an issue.

    Erin,我是Joe。醫師對5D掃描器的回饋確實非常好。我的意思是,那些真的在每位病人進診所時都用它來掃描的醫師,他們發現齲齒或蛀牙的比率,幾乎是肉眼可見或透過X光能看到的近2倍,這也為這些醫師帶來了大量新業務。因此,這些資訊多半來自EMEA地區,顯然是在美國以外,因為FDA尚未核准該功能。所以我們認為,這些近紅外線技術可用來看牙齒裂紋與齲齒,從醫師的現金流角度來看,對其所處理的病例很有幫助。其次,從病患角度來看,它也有助於更早識別問題,讓你能更主動地介入,在問題真正變嚴重之前先處理。

  • As far as 5D in the United States, I think we've said that I'm never going to guess when the FDA says yes. I've been in the Class II medical device business for too long. But our expectation is in some time in the first half that we'll get 5D approval through the FDA.

    至於美國的5D,我想我們已經說過,我永遠不會去猜FDA什麼時候會說可以。我在第二類(Class II)醫療器材產業待太久了。但我們的預期是,在上半年某個時間點,我們會取得FDA對5D的核准。

  • Operator

    Operator

  • Next question comes from the line of Chris Cooley with Stephens.

    下一個問題來自Stephens的Chris Cooley。

  • Christopher Cook Cooley - MD

    Christopher Cook Cooley - MD

  • And also, thank you for taking a shot at China. I know that's a really fluid situation for you guys this evening. Just from my perspective, can we go back to 30,000 feet and just looking at the guidance for '20 in terms of growth ex China. You're talking about towards the lower bound of the LRP plan there, so let's say 20% to 25%. Why wouldn't growth inflect higher after the deceleration from '18 to '19, which is pretty meaningful. Could you maybe just help us parse out whether it's the challenging part of comps, if it's the difference in the consumer mix, competition. Just want to try and understand why that wouldn't inflect back up with the strong volume growth that you're seeing globally here in 2018 and 2019, independent, obviously, of China.

    另外,也謝謝你們願意談中國的部分。我知道今晚對你們而言這是一個非常動態的情況。就我的角度,我們能否回到更宏觀的層面,看看2020年在不含中國(ex China)的成長指引?你們談到會接近LRP(長期計畫)區間的下緣,也就是說大約20%到25%。為什麼在2018到2019年出現相當明顯的減速之後,成長不會再度向上拐點?你能否協助我們拆解一下,是因為比較基期具挑戰、消費者組合差異、競爭等因素嗎?我想理解的是:在你們看到2018與2019年全球(顯然不含中國)出貨量強勁成長的情況下,為什麼成長不會再度回升?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Chris, this is John. It's a good question. I mean, when we look at the investments that we're making, we invest into, as you said, that long-term growth model, where there's international expansion. We're going to continue to expand and grow into countries. We're going to continue to grow our utilization, whether it's on the ortho side or the GP side. We look at how we exited, we felt really good about fourth quarter, felt good about coming into this year. But we want to make sure that as we invest and as we continue to grow, we can give you information that we see. And as we look at the year and as we look at our investments, this is the best information that we can get. Of course, as we invest, we always look for additional opportunities, whether it's growth in other markets, increased utilization and so on. And those are things that we'll do. China gets a lot of the headlines now because of what's happening there, but the rest of our business is a good growth opportunity for us, and we're making investments within those areas.

    Chris,我是John。這是個好問題。我的意思是,當我們看我們正在進行的投資時,我們投資於,如你所說的,那個長期成長模式,其中包含國際擴張。我們將持續擴張並進入更多國家成長。我們也會持續提升我們的使用率,不論是在矯正(ortho)端或是一般牙科(GP)端。回顧我們的收尾情況,我們對第四季感覺非常好,對進入今年也感覺良好。但我們想確保,當我們投資並持續成長時,我們能把我們所看到的資訊提供給你。而當我們看今年、看我們的投資時,這是我們能取得的最佳資訊。當然,隨著我們投資,我們也一直在尋找額外的機會,不論是其他市場的成長、使用率提升等等。這些都是我們會去做的事。中國因為那裡正在發生的事情而成為許多新聞焦點,但我們其餘業務對我們而言是很好的成長機會,我們也正在那些領域進行投資。

  • Operator

    Operator

  • The last question comes from the line of Ravi Misra from Berenberg Capital Markets.

    最後一個問題來自Berenberg Capital Markets的Ravi Misra。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • Two quick questions. Just on the balance sheet, both of them. Number one, just inventory days have been creeping up throughout the year. Historically, it's been a pretty good working capital business. Can you help me understand why that's the case and what's the kind of new normal expected there? And secondly, with almost $870 million on the balance sheet, just in terms of capital allocation, maybe help us think about any changes to the current kind of philosophy of share repurchases.

    兩個快速問題。都關於資產負債表。第一,存貨天數在今年一路緩步上升。過去這一直是個營運資金表現相當不錯的業務。你能幫我理解為什麼會這樣,以及那裡預期的新常態大概會是什麼嗎?第二,資產負債表上接近8.7億美元的現金,就資本配置而言,能否幫我們思考一下,對目前股份回購的整體理念是否會有任何改變?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Ravi, this is John. I'll take the first one on iTero or the balance sheet with the inventory. The majority of that increase is on the iTero side as we transition to products with Element 1 to Element 2 and then to 5D, there's just some timing related to that. But that as we start to sell more 5D and as we increase our volume on iTero, that inventory will come down. On the Invisalign side, it's pretty consistent to what our growth has been.

    Ravi,我是John。我先回答第一個,關於iTero或資產負債表上的存貨。那個增加的大部分來自iTero端,因為我們從Element 1轉換到Element 2,再到5D產品,這裡面有一些時點因素。但隨著我們開始賣出更多5D、並提高iTero的出貨量,那些存貨會下降。在Invisalign端,基本上與我們的成長趨勢相當一致。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I think, Ravi, on the cash on the balance sheet, obviously, this company is an amazing cash generator in that way. Yes, I just want to re-emphasize, Ravi, we're not in the general dentistry business, so don't look at us going out to broaden the portfolio in any particular way. We're building what we talked about when I closed about a digital platform and investing in that digital platform is where we're focused on. So when we have our Investor Day in May, we'll reapproach it in the sense of the share buyback and what we think we'll be doing with that cash in the future.

    我想,Ravi,關於資產負債表上的現金,很明顯,這家公司在這方面是非常出色的現金創造者。是的,我只想再次強調,Ravi,我們不在一般牙科業務裡,所以不要期待我們會以任何特定方式出去擴大產品組合。我們正在打造我在結語時提到的數位平台,而投資這個數位平台是我們的重點。因此,當我們在5月舉辦投資人日(Investor Day)時,我們會重新檢視股份回購的方向,以及我們認為未來會如何運用這些現金。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Thanks, Ravi. Thanks, everyone. That concludes our conference call today. We appreciate you taking the time. As a reminder, we did send out information today of the date for our Investor Day in May, May 12 in New York City. If you have any questions, please contact Investor Relations. Have a great day.

    謝謝你,Ravi。謝謝各位。今天的電話會議到此結束。感謝大家撥冗參與。提醒一下,我們今天已發出5月投資人日的日期資訊:5月12日,地點在紐約市。如有任何問題,請聯絡投資人關係部門。祝各位有美好的一天。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's teleconference. Thank you for your participation. You may disconnect your lines at this time and have a wonderful day.

    各位女士、先生,今天的電話會議到此結束。感謝各位的參與。您現在可以掛斷電話線,祝您有美好的一天。